UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 1 of 78 AN OPEN -LABEL, RANDO MIZED, PARALLEL -GROU P, 
SINGLE -DOSE BIOEQUIV ALENCE STUDY OF BIME KIZUMAB 
GIVEN AS 1X2ML OR 2X 1ML SUBCUTANEOUS INJ ECTION 
USING  AN AUTOINJECTOR IN HEALTHY STUDY 
PARTICIPANTS  
 
PROTOCOL UP0119 AMEN DMENT 1  
PHASE 1  
 
SHORT TITLE:  
A bioequivalence study of bimekizumab administered as 1x2mL or 2x1mL subcutaneously in 
healthy study participants.  
Sponsor:  
UCB Biopharma SRL  
Allée de la R echerche 60  
1070 Brussels  
BELGIUM  
Regulatory agency identifying number(s):  
Eudra CT Number:  2021 -005334 -41 
IND Number  128707  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 2 of 78 PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE 
Document History  
Document  Date  Type of amendment  
Amendment 1 21 Mar 2022  Substantial  
Original Protocol  23 Nov 2021  Not applicable  
Amendment 1 (21 Mar 2022 ) 
Overall Rationale for the Amendment  
This amendment addresses recommendations from the Standing Committee on Vaccination  for the 
provision of COVID -[ADDRESS_1136861] been implement in the protocol template. Additional changes 
include clarification of body weights for pairing of study participants, clarification of ex clusion 
criteria, clarification of footnotes in the Schedule of activities, and clarification of names of 
central laboratories.  
Section # and name  [CONTACT_111444]  
1.1 Synopsis,  
4.1 Overall  design,  
and  
6.3 Measures to minimize bias:  
randomization and blinding  Clarified that body weights in 
each pair should differ by ≤10kg 
and that ideally the participant’s 
body weight at admission 
(Day -1) should be used for 
pairing  Clarification  
1.3 Schedule of activities  Corrected footnote j to cl arify 
the HBc -Ab sample included 
both IgG and IgM  Correction  
2.3.1 Risk assessment for 
coronavirus disease 2019  
And 
5.3.4 Other restrictions  Added requirement for 
documentation of COVID -19 
vaccination at Screening for 
study participants in [LOCATION_013]  Addition  
5.2 Exclusion criteria  Renumbered criterion 23 as 23a , 
clarified alcohol equivalent 
volume , removed examples  Clarification  
8.3.7 Medical device  – adverse 
device effects and device 
presentation deficiencies  
and  
11 References  Corrected publication year of 
ISO [ZIP_CODE] to reflected updated 
version  Correction  
8.3.7 Medical device  – adverse 
device effects and device 
presentation deficiencies  
and subsections  Corrected section headings and 
terminology to align with 
changes in adverse device eff ect 
language in template  Correction  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136862] 
language in template  Addition  
Section 10.2 Appendix 2: 
Clinical laboratory tests  Clarified names of central 
laboratories per forming 
laboratory tests  Clarification  
Section 10.7 Appendix 7: 
Medical device presentation 
ADEs and Device Deficiencies:  
– definition and procedures for 
recording, evaluating, follow up, 
and reporting  
and subsections  Corrected section headings and 
terminology and deleted 
subsections to align with 
changes in adverse device effect 
language in template  Correction  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 4 of 78 SERIOUS ADVERSE EVEN T REPORTING  
 
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: [PHONE_301] 21  
Email  Global:  [EMAIL_311]  
 
SAFETY REPORTING OF ADVERSE EVENTS (SERI OUS AND 
NONSERIOUS) AND DEVI CE DEFICIENCIES  
Safety reporting of adverse events (24h)  
Email  Global : [EMAIL_311]  
Fax [PHONE_301] 21  
 
Reporting of device deficiencies (24h)  
Email  Global:  [EMAIL_15584]  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 5 of 78 TABLE OF CONTENTS  
1 PROTOCOL SUMMARY  ................................ ................................ ................................ . 9 
1.1 Synopsis  ................................ ................................ ................................ .........................  9 
1.2 Schema  ................................ ................................ ................................ .........................  12 
1.3 Schedule of activi ties ................................ ................................ ................................ ... 13 
2 INTRODUCTION  ................................ ................................ ................................ ...........  20 
2.1 Study rationale  ................................ ................................ ................................ .............  20 
2.2 Background  ................................ ................................ ................................ ..................  21 
2.3 Benefit/risk assessment  ................................ ................................ ................................  22 
2.3.1  Risk assessment for coronavirus disease 2019  ................................ ....................  22 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .................  25 
4 STUDY DESIGN  ................................ ................................ ................................ .............  26 
4.1 Overall design  ................................ ................................ ................................ ..............  26 
4.2 Scientific rationale for study design  ................................ ................................ ............  26 
4.3 Justification for dose  ................................ ................................ ................................ .... 27 
4.4 End of study definition ................................ ................................ ................................ . 27 
5 STUDY POPULATION  ................................ ................................ ................................ .. 27 
5.1 Inclusion criteria  ................................ ................................ ................................ ..........  27 
5.2 Exclus ion criteria  ................................ ................................ ................................ .........  28 
5.3 Lifestyle restrictions ................................ ................................ ................................ ..... 31 
5.3.1  Meals and dietary restrictions  ................................ ................................ ..............  31 
5.3.2  Caffeine, alcohol, and tobacco  ................................ ................................ .............  31 
5.3.3  Activity  ................................ ................................ ................................ ................  31 
5.3.4  Other restrictions  ................................ ................................ ................................ . 31 
5.4 Screen failures  ................................ ................................ ................................ ..............  32 
5.5 Rescreenin g ................................ ................................ ................................ ..................  32 
6 STUDY TREATMENTS/INV ESTIGATIONAL DEVICE  ................................ ............  32 
6.1 Treatments administered  ................................ ................................ ..............................  33 
6.1.1  Medical devices  ................................ ................................ ................................ ... 33 
[IP_ADDRESS]  Bime kizumab -AI-1mL  ................................ ................................ ..............  33 
[IP_ADDRESS]  Bimekizumab -AI-2mL  ................................ ................................ ..............  34 
6.2 Preparation, handling, storage, and accountability requirements  ................................  34 
6.2.1  Retention samples  ................................ ................................ ................................  35 
6.3 Measures to minimize bias: randomization and blinding  ................................ ............  35 
6.4 Treatment compliance  ................................ ................................ ................................ .. 36 
6.5 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 36 
6.5.1  Permitted concomitant treatments (medications and therapie s) ..........................  36 
6.5.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  .........................  37 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 6 of 78 6.6 Dose modification  ................................ ................................ ................................ ........  37 
6.7 Treatmen t after the end of the study  ................................ ................................ ............  37 
7 DISCONTINUATION OF S TUDY MEDICATION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ........  [ADDRESS_1136863]  ................................ ................................ ........  43 
[IP_ADDRESS]  Other safety topi[INVESTIGATOR_23254]  ................................ ................................ .... 43 
8.3.7  Medical device – adverse device effects and device presentation deficiencies  .... 43 
[IP_ADDRESS]  Time period for detecting medical device presentation deficiencies  ........  43 
[IP_ADDRESS]  Follow -up of device deficiencies ................................ ...............................  44 
[IP_ADDRESS]  Prompt r eporting of device deficiencies to the Sponsor  ............................  44 
[IP_ADDRESS]  Regulatory reporting requirements for device deficiencies .......................  44 
8.4 Safety signal detection  ................................ ................................ ................................ . 44 
8.5 Treatment of overdose  ................................ ................................ ................................ . 44 
8.6 Pharmacokinetics  ................................ ................................ ................................ .........  44 
8.7 Genetics ................................ ................................ ................................ ........................  45 
8.8 Pharmacodynamics  ................................ ................................ ................................ ...... 45 
8.9 Biomarkers  ................................ ................................ ................................ ...................  46 
8.10  Immunogenicity assessments  ................................ ................................ .......................  46 
8.11  Medical resource utilization and health economics  ................................ .....................  46 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 7 of 78 9 STATISTICAL CONSIDER ATIONS  ................................ ................................ .............  46 
9.1 Definition of analysis sets  ................................ ................................ ............................  46 
9.2 General statistical considerations  ................................ ................................ .................  47 
9.3 Planned efficacy/outcome analyses  ................................ ................................ .............  47 
9.4 Planned outcome analyses  ................................ ................................ ...........................  47 
9.4.1  Primary endpoint analyses  ................................ ................................ ...................  47 
9.4.2 Secondary endpoint analyses  ................................ ................................ ...............  47 
9.5 Planned safety and other analyses ................................ ................................ ................  47 
9.5.1  Safety analyses  ................................ ................................ ................................ ..... 47 
9.5.2  Immunogenicity analyses  ................................ ................................ ....................  48 
9.5.3 Other analyses  ................................ ................................ ................................ ...... 48 
[IP_ADDRESS]  Study participant disposition and characteristics  ................................ ...... 48 
9.6 Handling of protocol deviations ................................ ................................ ...................  48 
9.7 Handling of dropouts or missing data  ................................ ................................ ..........  49 
9.8 Planned interim analysis and data monitoring  ................................ .............................  49 
9.9 Determination of sample size  ................................ ................................ .......................  49 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS ... 50 
10.1  Appendix 1: Regulatory, ethical, and study oversight considerations  .........................  50 
10.1.1  Regulatory and ethical considerations  ................................ ................................ . 50 
10.1.2  Financial disclosure  ................................ ................................ .............................  50 
10.1.3  Informed consent process  ................................ ................................ ....................  51 
10.1.4  Data protection  ................................ ................................ ................................ ..... 51 
10.1.5  Committees structure  ................................ ................................ ...........................  51 
10.1.6  Data quality assurance  ................................ ................................ .........................  52 
[IP_ADDRESS]  Case Report form completion  ................................ ................................ .... 52 
[IP_ADDRESS]  Apps  ................................ ................................ ................................ ...........  53 
10.1.7  Data collection and source documents  ................................ ................................  53 
10.1.8  Study and site closure  ................................ ................................ ..........................  53 
10.1.9  Publication policy  ................................ ................................ ................................  54 
10.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ..........  55 
10.3  Appendix 3: Adverse events – definitions and procedures for recording, evaluating, 
follow up, and reporting  ................................ ................................ ...............................  57 
10.3.1  Definition of AE  ................................ ................................ ................................ .. 57 
10.3.2  Definition of SAE  ................................ ................................ ................................  58 
10.3.3  Recording and follow up of AE and/or SAE  ................................ .......................  59 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  .........  62 
10.5  Appendix 5: Genetics  ................................ ................................ ................................ ... 65 
10.6  Appendix 6: Liver safety – suggested actions and follow -up assessments  .................  66 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 8 of 78 10.7  Appendix 7: Medical device presentation ADEs and Device Deficiencies:  – definition 
and procedures for r ecording, evaluating, follow up, and reporting  ............................  68 
10.7.1  Definitions of a medical device presentation incident  ................................ .........  68 
10.7.2  Definition of ADE  ................................ ................................ ...............................  68 
10.7.3  Definition of device deficiency  ................................ ................................ ...........  68 
10.7.4  Recording and follow up of ADE and device deficiencie s ................................ .. 69 
10.8  Appendix 8: Rapid alert procedures  ................................ ................................ ............  71 
10.9  Appendix 9: Country -specific requirements  ................................ ................................  72 
10.10  Appendix 10: Abbreviations and trademarks  ................................ ..............................  73 
10.11  Appendix 11: Sample size estimation parameters  ................................ .......................  76 
10.12  Appendix 12: Protocol amendment history  ................................ ................................ . [ADDRESS_1136864] OF TABLES  
Table  1-1: Schedule of study assessments overview  ................................ .........................  13 
Table  1-2: Study assessments from dosing Day 1 to Day 3, 48h after IMP 
administration  ................................ ................................ ................................ .. 17 
Table  1-3: Study assessments from Day 4 to 10 after IMP administration  .......................  18 
Table  1-4: Study assessments from Day 13 to 140 after IMP administration  ...................  19 
Table  3-1: Objectives and estimands/endpoints  ................................ ................................  25 
Table  6-1: UP0119 treatments administered  ................................ ................................ ..... 33 
Table  10-1: Protocol -required safety laboratory assessments  ................................ .............  55 
Table  10-2: Highly effective con traceptive methods a ................................ ........................  63 
Table  10-3: Phase I liver chemistry stoppi[INVESTIGATOR_377035] -up assessments  ..............  [ADDRESS_1136865] OF FIGURES  
Figure  1-1: Study schematic  ................................ ................................ ...............................  12 
Figure  6-1: Bimekizumab -AI-1mL  ................................ ................................ .....................  34 
Figure  6-2: Bimekizumab -AI-2mL  ................................ ................................ .....................  34 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 9 of 78 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Proto col title:  
An open -label, randomized, parallel -group, single -dose bioequivalence study of bimekizumab 
given as 1x2mL or 2x1mL subcutaneous injection using an autoinjector in healthy study 
participants.  
Short Title:  
A bioequivalence study of bimekizumab administered as 1x2mL or 2x1mL subcutaneously in 
healthy study participants.  
Rationale:  
The bimekizumab 320mg dose was assessed in Phase 3 psoriasis [PSO] studies and was 
approved in the European Union (EU) on 20 Aug 2021 for the treatment of moderate to s evere 
PSO. Currently, the dose is administered as 2x1mL subcutaneous (sc) injections of 160mg. To 
provide additional options to healthcare professionals and patients, it is considered of benefit by 
[CONTACT_820207] 320mg device presentations (ie,  functional secondary packaging) 
where the dose can be delivered as a single 2mL sc injection. The primary objective of this study 
is, therefore, to compare the pharmacokinetics (PK) of bimekizumab 320mg when administered 
sc using a 2mL auto -injector (AI; bimekizumab -AI-2mL, test) versus 2x1mL auto -injector 
(bimekizumab -AI-1mL, reference) to support the development of the 2mL AI device 
presentation.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 10 of 78 Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To compare the PK of a single sc dose of BKZ when 
administered using the bimekizumab -AI-2mL 
presentation (test) versus the bimekizumab -AI-
2x1mL presentation (reference) in healthy study 
participants  • AUC, AUC (0-t), Cmax 
Secondary  
• To assess the safety and tolerability of a single sc 
dose of BKZ when admin istered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • TEAEs and treatment -emergent SAEs  
• To assess additional PK parameters of a single sc 
dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bim ekizumab -AI-2mL 
presentation in healthy study participants  • t½, tmax 
Other/exploratory  
• To assess additional PK parameters of a single sc 
dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • %AUC ex, CL/F, V z/F 
• To assess immunogenicity of a single sc dose of 
BKZ when administered using the bimekizumab -AI-
2x1mL or bimekizumab -AI-2mL presentation in 
healthy study participants  • Incidence of BKZ antidrug antibodies  
• To assess additiona l safety and tolerability of a 
single sc dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • Vital signs (pulse rate, BP, and 
tympanic body temperature)  
• Safety laboratory data (hematology 
[including coagulation/hemostasis 
tests], clinical chemistry, and 
urinalysis)  
• 12-lead ECG assessments  
AI=autoinjector; AUC=area under the plasma concentration -time curve from time zero to infinity; 
%AUC ex=percentage of the AUC extrapolated fro m C last; AUC (0-t)=area under the plasma concentration -time 
curve from time zero to the last quantifiable concentration; BKZ=bimekizumab; BP=blood pressure; 
CL/F=apparent total body clearance; C last=last observed quantifiable plasma drug concentration; 
Cmax=maximum observed plasma drug concentration; ECG=electrocardiogram; PK=pharmacokinetic; 
SAE=serious adverse event; sc=subcutaneous; TEAE=treatment -emergent adverse event; t ½=apparent terminal 
half-life; t max=time of occurrence of C max 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confi dential  Page 11 of 78 Overall Design  
This is a Phase 1, open label, randomized, parallel -group, single dose, 2 -arm bioequivalence 
(BE) study to compare the PK of bimekizumab  320mg when administered as either a 1x2mL or 
2x1mL sc injection in healthy male and female study participants using an AI pr esentation. The 
2 arms will be:  
1. Bimekizumab -AI-2mL (test)  
2. 2xBimekizumab -AI-1mL (reference)  
Number of Participants  
Assuming a dropout rate and nonevaluable study participants of approximately 10%, [ADDRESS_1136866] match the gender and weight (≤10kg difference  
between the 2 participants ) of the remaining participant being replaced and receive the same 
treatment as the participant being with drawn from treatment.  
Treatment Groups and Duration  
Each study participant will receive a single -dose administration of bimekizumab 320mg 
administered sc either using a single 2mL AI (bimekizumab -AI-2mL, test) or two 1mL AIs 
(bimekizumab -AI-1mL, reference) . The duration of the study will be approximately 168  days, 
including 27 days of Screening, admission on Day -1, an inhouse Treatment Period from Day 1 
to Day 3, Outpatient Visits until Day 112, and a Safety Follow -Up (SFU) Visit on Day 140. 
Randomization will occur on Day 1 prior to dosing.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 12 of 78 1.2 Schema  
Figure  1-1: Study schematic  
 
AI=autoinjector  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 13 of 78 1.3 Schedule of activities  
Table  1-1: Schedule of study assessments overview  
Assessments  Screening  Inhouse Treatment Period  Outpatient Visits  Early 
Withdrawala/ 
SafetyFollow -Up/ 
Visits  
Day -28 
to Day -2 Day -1 Day 1  
Day 1 
postdose 
to Day 3 
postdose  Days 4 to 
10 Days 13, 
16, 19, 
22, 25, 
and 28 
(±1 days)  Days 56, 
84, 112  
(±3 days)  Day 140  
(±3 day)  Admission  Pre-
dose  0 h 
Ambulatory (A)/inhouse (I) visit  A I A A A A 
Written informed consent  X         
Verification of inclusion/exclusion 
and withdrawal criteria  X X X       
Demographic data and lifestyle  X         
Medical/procedures history  X         
Urine drug and alcohol screen  X X        
TB test  
(QuantiFERON®-TB GOLD PLUS)b X         
TB questionnairea X         
Smoking habits/Fagerström test  X         
Randomizationc   X       
Pre-visit COVID -19 questioningd  X     X X X 
IMP administratione    X      
Physical examinationf X X   Xf Xf Xf Xf X 
Vital signsg, h X X X  X Xg Xg X X 
Body weight  X X       X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 14 of 78 Table  1-1: Schedule of study assessments overview  
Assessments  Screening  Inhouse Treatment Period  Outpatient Visits  Early 
Withdrawala/ 
SafetyFollow -Up/ 
Visits  
Day -28 
to Day -2 Day -1 Day 1  
Day 1 
postdose 
to Day 3 
postdose  Days 4 to 
10 Days 13, 
16, 19, 
22, 25, 
and 28 
(±1 days)  Days 56, 
84, 112  
(±3 days)  Day 140  
(±3 day)  Admission  Pre-
dose  0 h 
Height  X         
12-lead ECGh X X X  X X X X X 
Prior and concomitant medication  X X X  X X X X X 
Concomitant medical procedures  X X X  X X X X X 
Adverse events  X X X X X X X X X 
Device presentation deficiencies     Xi      
Serology j X         
SARS -CoV -2 RT -PCRk  X        
Hematologyl  X X   X X X X X 
Clinical chemistryl X X   X X X X X 
Coagulation/hemostasisl X X   X X X X X 
Urinalysis (dipstick) m X X   X X X X X 
Blood samples for BKZ plasma 
concentrationsn   X  X X X X X 
Blood samples for ADAbso    X    X X X 
Pregnancy testp X X     X X X 
Follicle -stimulating hormone testp X         
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 15 of 78 Table  1-1: Schedule of study assessments overview  
Assessments  Screening  Inhouse Treatment Period  Outpatient Visits  Early 
Withdrawala/ 
SafetyFollow -Up/ 
Visits  
Day -28 
to Day -2 Day -1 Day 1  
Day 1 
postdose 
to Day 3 
postdose  Days 4 to 
10 Days 13, 
16, 19, 
22, 25, 
and 28 
(±1 days)  Days 56, 
84, 112  
(±3 days)  Day 140  
(±3 day)  Admission  Pre-
dose  0 h 
A=ambulatory; Ab=antibody; ADAb=antidrug -antibody; AE=adverse event; BKZ=bimekizumab; BP=blood pressure; COVID -19=coronavirus disease  2019; 
ECG=electrocardiogram; FSH=follicle stimulating hormone; h=hour; HBc -Ab=hepatitis B core antibody; HBsAg=hepatitis B surface antigen; HCV -Ab=hepatitis C virus 
antibody; HIV=human immunodeficiency virus; HIV1/2 -Ab=HIV1/2 antibody; HIV1 -Ag=HIV1 antige n; I=inhouse; IgG=immunoglobulin G; IgM=immunoglobulin M; 
IMP=investigational medicinal product; PK=pharmacokinetic(s); RT -PCR=real -time reverse transcriptase polymerase chain reaction; SARS -CoV -2=severe acute respi[INVESTIGATOR_11520] 2; sc=subcuta neous; SFU=Safety Follow -Up; SOP=Standard Operating Procedure; TB=tuberculosis  
Note: At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the study but prior to the S FU Visit, if deemed necessary for the study 
particip ant’s safety and well -being. The same assessments as performed on the SFU Visit, or alternatively as advised by [CONTACT_737], should be perform ed if a study 
participant is attending an Unscheduled Visit during the study.  
a If a study participant withdr aws prior to completion of the study, an Early Withdrawal Visit will be conducted at the time of withdrawal and the same asse ssments planned for 
the SFU Visit will be performed.  
b Refer to UCB g -q-[ADDRESS_1136867] with persons having confirmed SARS -CoV -
2 infection. In case of signs/symptoms or contac t, the visit will be cancelled and reason for cancellation will be appropriately documented documented in the eCRF . 
e Bimekizumab will be administered as a sc injection as detailed in Section  6.1 
f A full physical examination will be performed at the Screening Visit, Day -1, and the Early Withdrawal/SFU Visit. On all other days (Days 2, 3, 9, 25, 56, 84, and 112) a 
physical examination is planned, it w ill be performed symptom -driven, ie, in case of an AE.  
g Vital signs include BP, pulse rate, and tympanic body temperature. At outpatient visits without regular vital signs measurements , only tympanic body temperature will be 
collected. The number of readi ngs to be collected will be determined by [CONTACT_820208].  
h During the inhouse treatment period, vital signs and ECGs should be measured/taken prior to blood sampling, where applicable,  with the study participant resting in the 
supi[INVESTIGATOR_562398] 3 minutes. Vital signs and ECGs will be measured on Day 1 at predose, at 1.5h, 5h, and 11h postdose, on Day 2 at 24h  postdose, and on Day 3 at 
48 hours postdose, then on Days 9, 25, 56, 84, 112, and 140.  
i As this is a single -dose study, device p resentation deficiencies are only to be captured on Day 1 (ie, the day when IMP is administered during the inhouse treatment period).  
j Serology variables include HbsAg, HBc -Ab (both IgG and IgM), HCV -Ab, HIV1 -Ab, HIV1 -Ag, and HIV -2 Ab.  
k The frequency of SARS -CoV -2 RT -PCR  will be assessed in compliance site -specific procedures and local regulations.  
l Blood sampling for hematology (including coagulation and hemostasis) and clinical chemistry will be performed at the Screenin g Visit, and Days -1, 2, 9, 25, 56, 84, 112, and 
the SFU Visit.  
m Urinalysis via dipstick will be performed at Screening, Day -1, Days 2, 9, 25, 56, 84, 112, and 140.  
n The PK sampling time points will be as follows: predose (within a maximum of 60 minutes prior to dosing), 1.5h, 5h, 24h,  48h postdose, and from Day 4 onwards at every 
visit (ie, Days 4 to 10, 13, 16, 19, 22, 25, 28, 56, 84, 112, and 140).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 16 of 78 Table  1-1: Schedule of study assessments overview  
Assessments  Screening  Inhouse Treatment Period  Outpatient Visits  Early 
Withdrawala/ 
SafetyFollow -Up/ 
Visits  
Day -28 
to Day -2 Day -1 Day 1  
Day 1 
postdose 
to Day 3 
postdose  Days 4 to 
10 Days 13, 
16, 19, 
22, 25, 
and 28 
(±1 days)  Days 56, 
84, 112  
(±3 days)  Day 140  
(±3 day)  Admission  Pre-
dose  0 h 
o  ADAb samples will be taken predose and on Days 13, 28, 56, 84, 112, and 140; blood samples will be processed as specified in the labor atory manual. If feasible, an 
additional blood sample for PK and ADAb analysis should be collected from participants who develop a hypersensitivity reactio n. The sample should be obtained close to the 
time of the ev ent using an unscheduled visit if needed.  
p Pregnancy tests will be performed at the Screening Visit, Day -1, Days 28, 56, 84, 112, and Day 140. Prior to dosing (at Screening and Day -1), the test should be performed in 
serum; post dosing the test may be performed in urine. The FSH test will be pe rformed in postmenopausal women at the Screening Visit. Additional details are provided in 
Appendix 4 (Section  10.4). 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 17 of 78 Table  1-2: Study assessments from dosing Day 1 to Day 3, 48h after IMP administration  
Assessments  Day 1  Day 2  Day 3  
Predose  Dosing 0h  1.5h 3h 5h 11h 24h 48h 
Physical examination        X X 
Vital signsa X  X  X X X X 
12-lead ECG  X  X  X X X X 
Hematology        X  
Clinical chemistry        X  
Coagulation/hemostasis        X  
Urinalysis (dipstick)        X  
IMP administration   X       
Blood samples for BKZ 
plasma concentrations  X b  X  X  X X 
Blood samples for ADAbs  X        
Concomitant medication  X  X X X X X X 
Concomitant medical 
procedures  X  X X X X X X 
Adverse events  X X  X X X X X X 
Device presentation 
deficiencies   Xc       
ADAb=antidrug antibody; BKZ=bimekizumab; ECG=electrocardiogram; h=hour; IMP=investigational medicinal product; SOP=standard operating procedure  
a The number of readings to be collected will be determined by [CONTACT_820208].  
b Within a maximum of 60 minutes prior to dosing . 
c As this is a single -dose study, device presentation deficiencies are only to be captured on Day 1 (ie, the day when IMP is administered during th e inhouse treatment period).  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 18 of 78 Table  1-3: Study assessments from Day 4 to 10 after IMP administration  
Assessment  Day 4  Day 5  Day 6  Day 7  Day 8  Day 9  Day 10  
Physical examination       X  
Vital signsa Xa Xa Xa Xa Xa X Xa 
12-lead ECG       X  
Hematology       X  
Clinical chemistry       X  
Coagulation/hemostasis       X  
Urinalysis (dipstick)       X  
Blood samples for BKZ plasma 
concentrations  X X X X X X X 
Concomitant medication  X X X X X X X 
Concomitant medical procedures  X X X X X X X 
Adverse events  X X X X X X X 
BKZ=bimekizumab; ECG=electrocardiogram; IMP=investigational medicinal product; SOP=standard operating procedure  
a At outpatient visits  without regular vital signs measurements , only tympanic body temperature will be collected.  The number of readings to be collected will be determined by 
[CONTACT_820208].  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 19 of 78 Table  1-4: Study assessments from Day 13 to 140 after IMP administration  
Assessment  Day 13  Day 16  Day 19  Day 22  Day 25  Day 28  Day 56  Day 84  Day 112  Day 140  
Pre-visit COVID -19 questioninga X X X X X X X X X X 
Physical examination      X  X X X X 
Vital signsb Xb Xb Xb Xb X Xb X X X X 
Body weight           X 
12-lead ECG      X  X X X X 
Hematology      X  X X X X 
Clinical chemistry      X  X X X X 
Coagulation/hemostasis      X  X X X X 
Urinalysis (dipstick)      X  X X X X 
Urine pregnancy test       X X X X X 
Blood samples for BKZ plasma 
concentrations  X X X X X X X X X X 
Blood samples for ADAbs  X     X X X X X 
Concomitant medication  X X X X X X X X X X 
Concomitant medical procedures  X X X X X X X X X X 
Adverse events  X X X X X X X X X X 
ADAb=antidrug antibody; BKZ=bimekizumab; COVID -19=coronavirus disease 2019; ECG=electrocardiogram; eCRF=electronic Case Report form; IMP=investigational 
medicinal product; SARS -CoV -2=severe acute respi[INVESTIGATOR_6507] 2; SOP=standard operating procedure  
a Within [ADDRESS_1136868] with persons having confirmed SARS -CoV -
2 infection. In case of signs/symptoms or contact, the visit will be cancelled and reason for cancellation will be appropriat ely documented in the eCRF.  
b At outpatient visits without regular vital signs measurements , only tympanic body temperature will be collected . The number of readings to be collected will be determined by 
[CONTACT_820208].  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 20 of 78 2 INTRODUCTION  
Bimekizumab is a humanized, full-length monoclonal antibody (mAb) of immunoglobulin G1 
(IgG1) subclass with 2 identical antigen binding regions that selectively binds with high affinity 
to interleukin (IL) -17A, IL -17F, and IL -17AF cytokines. This property makes bimekizumab 
distinctly  different from the other IL -17-targeting agents, like secukinumab and ixekizumab 
(selective anti -IL-17A cytokine targeting mAb) or brodalumab (anti -IL-17 receptor targeting 
mAb). Bimekizumab -SS-1ml and bimekizumab -AI-1ml device presentations were approved  in 
the EU on [ADDRESS_1136869] demonstrated efficacy in study participants with 
psoriatic arthritis (PsA), axial spondyloarthritis  (axSpA), and hidradenitis suppurativa  (HS) and 
parallel development programs in these inflammatory diseases are ongoing.  
As of the current Investigator’s Brochure (IB) clinical cutoff date of [ADDRESS_1136870] been comple ted: 
• First-in-human study UP0008  
• Bioavailability studies RA0124 and UP0031  
• Phase  1 studies PA0007, UP0042, UP0033, UP0034, and UP0074  
• Phase 2 studies PS0018 (open -label extension [OLE] of PS0016), and HS0001  
• Phase  2a studies RA0123, UC0011 (discontinued st udy), PS0016, and AS0013  
• Phase  2b studies PS0010, PS0011 (OLE of PS0010), PA0008, PA0009, and AS0008  
• Phase 3 studies PS0008, PS0009, PS0013, DV0002, and DV0006  
The ongoing and planned studies with bimekizumab, as well as additional information on the 
clinical and nonclinical data for bimekizumab are available in the current version of the IB.  
2.1 Study rationale  
The bimekizumab 320mg dose was assessed in Phase 3 psoriasis [PSO] studies and was 
approved in the EU on 20 Aug 2021 for the treatment of moderate to s evere PSO. Currently, the 
dose is administered as 2x1mL sc injections of 160mg. To provide additional options to 
healthcare professionals and patients, it is considered of benefit by [CONTACT_820209] 320mg device presentations (ie, functional sec ondary packaging) where the dose 
can be delivered as a single 2mL sc injection. The primary objective of this study is, therefore, to 
compare the PK of bimekizumab 320mg when administered sc using a 2mL AI (bimekizumab -
AI-2mL, test) versus 2x1mL AI (bimeki zumab -AI-1mL, reference) to support the development 
of the 2mL AI device presentations.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 21 of 78 2.2 Background  
UCB is currently developi[INVESTIGATOR_007] 4 self -injection, single -use, device presentations, including two 
1mL presentations (bimekizumab -SS-1mL and bimekizumab -AI-1mL) a nd two 2mL 
presentations (bimekizumab -SS-2mL and bimekizumab -AI-2mL), to provide study participants 
with multiple needle -safe self -injection options. The bimekizumab -SS-1mL and the 
bimekizumab -SS-2mL device presentations provide study participants with con trol over the 
self-injection process (eg,  needle visibility, skin penetration by [CONTACT_79825], control speed of 
self-injection) while the bimekizumab -AI-1mL and the bimekizumab -AI-2mL device 
presentations provide study participants with a more automated self -injection.  
Clinical use substudies demonstrated that study participants with moderate to severe chronic 
PSO (DV0002 and DV0006) could self -inject bimekizumab across all 4  device presentations 
(bimekizumab -SS-1mL, bimekizumab -AI-1mL, bimekizumab -SS-2mL, and bi mekizumab -AI-
2mL) in a safe and effective manner. The bimekizumab -SS-1mL and bimekizumab -AI-1mL 
presentations were approved in the EU on 20  Aug 2021 for the treatment of moderate to severe 
PSO.  
UP0033 (EudraCT number: 2017 -004403 -48) was a single -dose heal thy participant study that 
investigated the PK of bimekizumab -SS-1mL (test 1; P5 drug substance) or bimekizumab -AI-
1mL (test 2; P5 drug substance) in comparison to the PK of bimekizumab 320mg when 
administered sc with the bimekizumab -True North (TN; refere nce; P4 drug substance). 
Bioequivalence was demonstrated across device presentations and an acceptable safety profile 
was demonstrated.  
UP0068 (UP0068 -EudraCT number: 2019 -002378 -30) was a single -dose healthy participant BE 
study that investigated the PK of bimekizumab 320mg when administered sc using the 
bimekizumab -SS-2mL presentation (test 1) versus the bimekizumab -SS-1mL presentation 
(reference 1) or the bimekizumab -AI-2mL presentation (test 2) versus the bimekizumab -AI-1mL 
presentation (reference 2). This study was closed prematurely, prior to enrollment of all study 
participants, due to coronavirus disease 2019 (COVID -19) and several lock -downs that delayed 
recruitment. BE was demonstrated for the 2mL SS but the sponsor was not able to conclude that 
BE was demonstrated for the 2mL AI device.  
UP0119 is an open -label, randomized, parallel -group, single -dose BE study of bimekizumab 
given as 1x2ml or 2x1ml sc injection in healthy study participants using the 
bimekizumab -AI-2mL presentation (test) versus th e bimekizumab -AI-2x1mL presentation 
(reference).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 22 of 78 2.3 Benefit/risk assessment  
Participation in this study does not have any therapeutic benefit for the healthy study 
participants. Healthy study participants will benefit from complete health check -ups and regula r 
routine blood tests throughout the course of the study. Nonetheless, the participation of healthy 
study participants in the study is of importance to the patients and the development of the 
bimekizumab -AI-2mL for administration of bimekizumab. Currently,  bimekizumab 320mg is 
administered as 2x1mL sc injections; therefore, UCB considers it a beneficial option for 
healthcare professionals and patients to administer bimekizumab 320mg as a single 1x2mL sc 
injection.  
Healthy study  participants who participate in this study may be exposed to the:  
• Risks of the study procedures  
• Known and unknown risks related to the exposure to the IMP  
Procedure -related risks  
The use of an indwelling cannula for blood sampling may be accompanied by [CONTACT_820210], by [CONTACT_656814]. After initial irritation, the 
presence of an indwelling cannula is usually painless and hardly noticeable. The same applies to 
vein puncturing for further blood sampling. In very rare cases, a nerve might be injured while 
inserting the cannula. This could be followed by [CONTACT_820211], reduced sensitivity, and/or pain.  
The total volume of blood drawn during the entire study per study participant is estimated at 
approximately 450m L. No health -related risk to healthy study participants is expected from this 
blood withdrawal.  
Drug -related risks and safety measures  
Bimekizumab has a generally favorable clinical safety profile, and the drug is not associated with 
serious adverse events  (SAEs) that would suggest a high risk to study participants in this study.  
The main safety concerns associated with bimekizumab include an increase in the risk for 
infection, in particular nonserious upper respi[INVESTIGATOR_6014]. Other types of nons erious 
infections (gastrointestinal, ear infection, conjunctivitis, bronchitis, mucocutaneous fungal 
infections) have also been commonly reported. The risk to study participants in this study will be 
minimized by [CONTACT_820212] 320mg, dosed only once, by [CONTACT_820213], 
and that all study participants will be screened for chronic infections, including tuberculosis 
(TB).  
More detailed information a bout the known and expected benefits and risks and reasonably 
expected AEs of bimekizumab may be found in the current IB.  
2.3.1  Risk assessment for coronavirus disease 2019  
Bimekizumab is a humanized, full -length IgG monoclonal antibody, with high affinity for b oth 
human IL -17A and IL -17F. While the risk related to severe acute respi[INVESTIGATOR_18960] 2 (SARS -CoV -2) or COVID -[ADDRESS_1136871] as a determining factor regarding the protective or 
pathologic role of IL -17 during viral infection and was associated with the exacerbated 
pathology following viral infections, such as Epstein Barr Virus in mice (Ohta et al, 2013). There 
is growing evidence that inhibition of IL -[ADDRESS_1136872].  
Based on thes e assumptions, the study is feasible in the appropriate population of healthy study 
participants. The risk of the study participants to be exposed to SARS -CoV -2 or to suffer from 
COVID -19 will be acceptable in comparison to the general population. However,  the risk of 
exposure to infected people cannot be completely excluded as the participants may need to share 
public spaces and communal areas with other members of the public (eg, commute to the site) 
and have additional human contact (eg, with site staff and other participants of the clinical 
study).  
Measures to mitigate the additional risks caused by [CONTACT_4113] -19 are:  
• This study will start enrolling only when the Sponsor and contract research organization 
(CRO) in collaboration deem it is safe to start the st udy. 
• Current national laws and local recommendations for prevention of pandemic will be strictly 
adhered to.  
• In [LOCATION_013], at the time of Screening, study participants must provide documentation of 
COVID -19 vaccination corresponding to the recommendation of the Standing Committee on 
Vaccination . 
• Study participants will be closely monitored for any signs and symptoms of COVID -19, 
including fever, dry cough, dyspnea, sore throat, and fatigue throughout the study. Once 
clinical signs of infection are reported by  [CONTACT_4317], the Investigator needs to determine 
whether samples can be collected and safety data can be recorded on site. If not, AEs and 
concomitant medications will be obtained via phone calls. Tympanic body temperature 
measurements during inhouse sta y and outpatient visits will be implemented.  
• The Investigator will not dose participants upon identification of any signs of COVID -19 
infection within the previous 14 days.  
• Confirmation of COVID -19 by [CONTACT_820214] t ests: 
a SARS -CoV -2 real -time reverse transcriptase polymerase chain reaction (RT -PCR) will be 
conducted on admission and participants with a negative test will be randomized.  
• The probability of virus transmission will be controlled as much as possible by:  
[CONTACT_261558].
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 24 of 78 − Advice for study participants to adhere to local requirements for social distancing and to 
minimize potential exposure to and/or transmission of the virus that causes COVID -19. 
− All participants within 24 hours of the indicated visit will be questioned (as per the 
schedule of activities) for assessing COVID -[ADDRESS_1136873] with a person who has tested positive for SARS -CoV -2. If applicable, 
participants will be referred to the local health care system for further follow up and 
treatment.  
− Physical distancing and person -to-person contact [CONTACT_820215].  
− Personal protect ive equipment will be used by [CONTACT_19288] (eg, surgical face mask, 
gloves) and staff (for example but not limited to masks, gloves, protectors, medical suits) 
as guided by [CONTACT_5277].  
Logistical improvements of the site and structural measur es of the study site building were 
implemented to further improve physical distancing.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 25 of 78 3 OBJECTIVES AND ENDPO INTS  
Table  3-1: Objectives and estimands/endpoints  
Objectives  Endpoints  
Primary  
• To compare the PK of a single sc dose of BKZ when 
administered using the bimekizumab -AI-2mL 
presentation (test) versus the bimekizumab -AI-
2x1mL presentation (reference) in healthy study 
participants  • AUC, AUC (0-t), Cmax 
Secondary  
• To assess the safety and tolerability of a single sc 
dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • TEAEs and treatment -emergent SAEs  
• To assess additional PK paramet ers of a single sc 
dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • t½, tmax 
Other/exploratory  
• To assess additional PK parameters of a single sc 
dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • %AUC ex, CL/F, V z/F 
• To assess immunogenicity of a single sc dose of 
BKZ when administered using the bimekizumab -AI-
2x1mL or bimekizumab -AI-2mL presentation in 
healthy study participants  • Incidence of BKZ antidrug antibodies  
• To assess additional safety and tolerability of a 
single sc dose of BKZ when administered using the 
bimekizumab -AI-2x1mL or bimekizumab -AI-2mL 
presentation in healthy study participants  • Vital signs (pulse rate, BP, and 
tympanic body temperature)  
• Safety laboratory data (hematology 
[including coagulation/hemostasis 
tests], clinical chemistry, and 
urinalysis)  
• 12-lead ECG assessments  
AI=autoinjector; AUC=area under the plasma concentration -time curve from time zero to infinity; 
%AUC ex=percentage of the AUC extrapolated from C last; AUC (0-t)=area under the plasma concentration -time 
curve from time zero to the last quantifiable concentration; BKZ=bimekizumab; BP=blood pressure; 
CL/F=apparent total b ody clearance; C last=last observed quantifiable plasma drug concentration; 
Cmax=maximum observed plasma drug concentration; ECG=electrocardiogram; PK=pharmacokinetic; 
SAE=serious adverse event ;sc=subcutaneous; TEAE=treatment -emergent adverse event; t ½=app arent terminal 
half-life; t max=time of occurrence of C max 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 26 of 78 4 STUDY DESIGN  
4.1 Overall design  
This is a Phase 1, open label, randomized, parallel -group, single dose, 2 -arm BE study to 
compare the PK of bimekizumab  320mg when administered as either a 1x2mL or 2x1mL sc 
injection in healthy male and female study participants using an AI presentation. The 2 arms will 
be: 
1. Bimekizumab -AI-2mL (test)  
2. 2xBimekizumab -AI-1mL (reference)  
The aim of this study is to demonstrate the BE of bimekizumab administered as either 1 x2mL or 
2x1mL sc injections using the bimekizumab -AI presentation in healthy study participants.  
Approximately 120 healthy male and female study participants will participate at a maximum of 
2 centers in the study (approximately 60  study participants in ea ch of 2 arms). Enrollment 
between the 2 sites will be balanced, with an approximate 1:1 ratio . Each study participant will 
receive a single dose administration of bimekizumab 320mg, as either 1x2mL or 2x1mL sc 
injections.  
Each eligible study participants will be matched with another participant for gender and body 
weight prior to randomization. The intention is that the body weights in each pair should differ 
by ≤10kg. Ideally, the participant’s body weight at admission (Day -1) should b e used for 
pairing. One participant within each pair will be randomly allocated to receive 1  of the 2 
treatments; the other participant will be allocated to the other treatment.  
The duration of the study will be approximately 168  days, including 27 days of  Screening, 
admission on Day -1, an inhouse Treatment Period from Day 1 to Day 3, Outpatients Visits until 
Day 112, and a SFU Visit on Day 140. Randomization will occur on Day 1 prior to dosing.  
4.2 Scientific rationale for study design  
The study design for UP 0119 is based on the recommendation of the guideline on the 
investigation of BE and the feedback received from the European Medicine Agency (EMA) in 
the Scientific Advice procedure EMEA/H/SA/3306/1/FU/1/2017/III (Sep 2017) on the 1mL 
device presentations a nd from FDA on the 1mL and 2mL device presentations (Aug 2017, 
Mar 2018, and Nov 2019). The parallel design was chosen with regard to the long half -life of 
bimekizumab of approximately 28 days.  
UCB is currently developi[INVESTIGATOR_007] 4 self -injection, single -use, device presentations, including two 
1mL presentations (bimekizumab -SS-1mL and bimekizumab -AI-1mL) and two 2mL 
presentations (bimekizumab -SS-2mL and bimekizumab -AI-2mL), to provide study participants 
with multiple needle -safe self -injection options. The bimekiz umab -SS-1mL and the 
bimekizumab -SS-2mL device presentations provide study participants with control over the 
self-injection process (eg,  needle visibility, skin penetration by [CONTACT_79825], control speed of 
self-injection) while the bimekizumab -AI-1mL and the bi mekizumab -AI-2mL device 
presentations provide study participants with a more automated self -injection. The aim of this 
study is to demonstrate the BE of bimekizumab administered as either 1x2mL or 2x1mL sc 
injections using the bimekizumab AI in healthy study participants.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136874] completed the study if he/she has completed all phases 
of the study including the Day [ADDRESS_1136875] scheduled procedure shown in the 
schedule of activities (Section  1.3). 
The end of the study is defined as the date of the last scheduled procedure shown in the schedule 
of activities for the last study participant in the study.  
5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclusion criteria  
Study participants are eligible to be included in the study only if all of the following criteria 
apply:  
Age 
1. Study participant must be ≥18 years and ≤65 years of age inclusive, at the time of signing the 
informed consent.  
Type of study  participant  
2. Study participants  who are overtly healthy as determined by [CONTACT_227546], physical examinat ion, vital signs, 12 -lead electrocardiogram (ECG), and 
laboratory tests, during the Screening Period and on admission.  
3. Study participant has a body temperature between 35.0°C and 37.5°C, inclusive, at Screening 
and on admission.  
Weight  
4. Body weight minimum of 50kg for male and 45kg for female study participants and a 
maximum of 100kg for all study participants,  and body mass index (BMI) within the range 
18 to 32 kg/m2 (inclusive) at the Screening Visit.  
Sex 
5. Male or female. Contraception guidelines (as per the  standard UCB contraceptive guideline) 
will be applicable.  
− A male study participant must agree to use contraception as detailed in Appendix 4 
(Section  10.4) of this protocol during the inhouse treatment period and for at least 
20 weeks after the administration of study treatment, and refrain from donating sperm 
during this period.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 28 of 78 − A female study participant is eligible to participate if she is not pregnant (see 
Appendix  4; Section  10.4), not breastfeeding, and at least one of the following conditions 
applies:  
◦ Not a woman of childbearing potent ial (WOCBP) as defined in Appendix 4  
OR 
◦ A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 during the 
inhouse  treatment period and for a period of 20 weeks after the administration of 
IMP.  
Informed consent  
6. An Independent Ethics Committee  (IEC) -approved written Informed Consent Form (ICF) is 
signed and dated by [CONTACT_820216] -specific 
assessment at the Screening Visit,  as described in Appendix 1 (Section  10.1.3 ). 
5.2 Exclusion criteria  
Study participants  are excluded from the study if any of the following criteria apply:  
Medical conditions  
1. History or presence of cardiovascular, respi[INVESTIGATOR_696], hepatic , renal, gastrointestinal (including 
inflammatory bowel disease), endocrinological, hematological, or neurological disorders 
constituting a risk when taking the study intervention; or interfering with the interpretation of 
data.  
2. Study participant has any m edical or psychiatric condition that, in the opi[INVESTIGATOR_684], could jeopardize or would compromise the study participant’s ability to 
participate in this study.  
3. Study participant has a current history of alcohol or drug use disorder, as defined  in 
Diagnostic and Statistical Manual of Mental Disorders (DSM) V, within the previous 1  year 
prior to the Screening Visit.  
4. Study participant has a known hypersensitivity to any components of the bimekizumab 
(and/or an investigational device) as stated in this protocol.  
5. Study participant has cardiovascular or cerebrovascular disease, including hypertension, 
angina, ischemic heart disease, transient ischemic attacks, stroke, peripheral arterial disease 
sufficient to cause symptoms, and/or requires therapy to  maintain stable status.  
6. Study participant has an active infection or history of infections as follows:  
− Any active infection (except common cold) within 14 days prior to Screening Visit  
− A serious infection, defined as requiring hospi[INVESTIGATOR_352156] -infectives within 
2 months prior to the Screening Visit  
− A history of opportunistic, recurrent, or chronic infections that, in the opi[INVESTIGATOR_684], might cause this study to be detrimental to the study participant. 
Opportunistic infections are in fections caused by [CONTACT_397144] (eg, 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 29 of 78 pneumocystis jirovicii, cryptococcosis) or unusually severe infections caused by [CONTACT_119957] (eg, cytomegalovirus, herpes zoster).  
7. Study participant has a history of a positive TB test or evidence of possible  TB or latent TB 
infection at Screening Visit. Refer to g -q-100573 Tuberculosis Detection Procedure 
Guideline for details regarding TB infection status, detection procedures, and the related 
exclusion criteria.  
Prior/Concomitant therapy  
8. Study participants receiving any live (includes attenuated) vaccination within the 8 weeks 
prior to the Screening Visit (eg, inactivated influenza and pneumococcal vaccines are 
allowed, but nasal influenza vaccination is not permitted). Live vaccines are not allowed 
during t he study or for [ADDRESS_1136876] 
(IMP).  
9. Past or intended use of prescription medication within 14 days or 5 half -lives prior to dosing. 
Specific medications listed in Section  6.5.1  may be allowed.  
10. Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) 
within 3 months or 5 half -lives (whichever is longer) prior to dosing.  
Prior/Concurrent clinical study experience  
11. Study participant has previously participated in this study or a study participant has 
previously been assigned to bimekuzimab treatment in any other study.  
12. Exposure to [ADDRESS_1136877] 30 days before signing the ICF in any 
other clinical study involving an investigational study intervention or any other type of 
medical research.  
Diagnostic assessme nts 
14. Study participant has concurrent acute or chronic viral hepatitis B or C or human 
immunodeficiency virus (HIV) infection. Study participants who have evidence of, or tested 
positive for hepatitis B or hepatitis C are excluded. A positive test for the h epatitis B virus 
(HBV) is defined as:  
− Positive for hepatitis B surface antigen (HBsAg+); or  
− Positive for anti -hepatitis B core antibody (HBc -Ab+) (IgM)  
A positive test for the hepatitis C virus (HCV) is defined as:  
− Positive for hepatitis C antibody (anti -HCV-Ab), and  
− Positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction)  
15. Study participant has any of the following hematology values at Screening Visit and Day -1: 
− For women, hemoglobin <10.5g/dL; for men, <13.0g/dL  
− Absolute neutr ophil count <1.5x109/L 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 30 of 78 16. Study participant has alanine transaminase (ALT), aspartate aminotransferase (AST), or 
alkaline phosphatase (ALP) >1.0x upper limit of normal (ULN).  
17. Study participant has total bilirubin >1.0xULN (isolated bilirubin <1.5xULN is accep table if 
bilirubin is fractionated and direct bilirubin <35%).  
18. Study participant has current or chronic history of liver disease or known hepatic or biliary 
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).  
19. Study particip ant has 12 -lead ECG with changes considered to be clinically significant (eg, 
QT interval corrected using Fridericia’s formula >450ms, bundle branch block, or evidence 
of myocardial ischemia) at Screening Visit or on Day -1. 
20. Study participant has abnormal blood pressure (BP) at the Screening Visit and on Day -1 as 
follows: mean systolic BP ≥140mmHg; mean diastolic BP ≥90mmHg. Study participants 
with a BP within this range but who, in the opi[INVESTIGATOR_689], have a high risk for 
cardiovascular accid ent based on, eg, family anamneses, smoking, BMI, or lipid spectrum 
can be excluded.  
Other exclusions  
21. Study participant has made a blood donation of a blood loss of more than 400mL of blood or 
blood products within 90 days prior to admission (Day -1) or pl ans to donate blood during 
the study.  
22. Female study participant who is pregnant, or plans to become pregnant during the study, or 
lactating, or sexually active with childbearing potential who is not using a medically accepted 
birth control method (see Appen dix 4).  
23a. Study participant has an alcohol consumption of more than 21 units (males) or 14 units 
(females) of alcohol per week ( 1 unit of alcohol is equivalent to 12.5mL ethanol at room 
temperature ). 
24. Study participant tests positive for alcohol or d rugs (urine test) at Screening or Day -1. 
25. Study participant smokes >10 cigarettes per day or has a score of >[ADDRESS_1136878] 
for Nicotine Dependence.  
26. Study participant has a high consumption of xanthine -containing products (≥ 300mg of 
xanthine -equivalent per day) [1 cup of coffee ≈ 100mg of caffeine; 1 cup of tea ≈ 30mg of 
caffeine; 1 glass of cola ≈ 20mg of caffeine].  
27. Study participant is not willing to avoid heavy physical exertion 48 hours before each 
assessment visit.  
28. Vulner able study participants (eg, participants kept in detention, protected adults under 
guardianship or trusteeship, and soldiers or participants committed to an institution by 
[CONTACT_451579]), employees of the Sponsor or the contract research  
organization (CRO) with direct involvement in the proposed study or other studies under the 
direction of the Investigator or the CRO, as well as family members of the employees or the 
Investigator.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136879] result for seve re acute respi[INVESTIGATOR_18960]  2 (SARS -CoV -2) in real -time reverse transcriptase polymerase chain 
reaction  (RT-PCR) on the admission sample.  
30. Study participant has clinical signs and symptoms consistent with COVID -19, eg fever, dry 
cough, dys pnea, sore throat, fatigue, or confirmed infection by [CONTACT_820217] 14 days prior to Screening or on admission.  
31. Study participant who had severe course of COVID -19 (ie, hospi[INVESTIGATOR_059], extracorporal 
membrane oxygenati on, mechanically ventilated).  
32. Study participant has active neoplastic disease or history of neoplastic disease within 5 years 
of Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma in 
situ that has been definitively tr eated with standard of care).  
5.[ADDRESS_1136880] 48 hours before each blood 
collection for clinical laboratory tests. Study participants may engage in light recreational 
activities during the study.  
5.3.4  Other restrictions  
During a pandemic or other exceptional circumstance (eg, hurricanes) regulatory authorities 
accompanied by [CONTACT_820218]. In 
such situation site personnel and study participants may need to adhere and implement these 
safety measures.  
Due to the exceptional circumstance of the evolving COVID -19 pandemic, study participants are 
advised to adhere to local requirements while ambulatory, to minimize potential exposure to 
and/or transmi ssion of the virus that causes COVID -19. 
In [LOCATION_013], at the time of Screening, study participants must provide documentation of COVID -19 
vaccination corresponding to the recommendation of the Standing Committee on Vaccination . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 32 of 78 5.4 Screen failures  
Screen failur es are defined as study participants who consent to participate in the clinical study 
but are not subsequently randomly assigned to study treatment. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure study participants to 
meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failures) may be 
rescreened (Section  5.5). 
Tests that result in ALT, AST,  or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes rescreening.  
5.5 Rescreening  
Per investigator discretion, study participants may be rescreened once under conditions such as 
the following:  
• Study participant falls  outside the Screening Period  
• If a study participant does not meet the inclusion criteria at Screening or on Day -1 due to an 
out-of-range laboratory result or a minor illness, he/she can be rescreened once at the 
discretion of the Investigator. Provided a ll inclusion criteria are met at the second screening, 
the study participant can be included.  
Study participants may be included if the repeat values for the laboratory screening criteria are 
within normal ranges and/or if repeat values show normalization of the out -of-range safety 
laboratory values, and/or after the study participant makes a complete recovery from the mild or 
moderate illness and if all other screening criteria are met.  
Rescreened study participants are assigned a new study participant num ber from the number 
assigned at the initial screening.  
6 STUDY TREATMENTS/INV ESTIGATIONAL DEVICE  
In this study, the term IMP refers to the bimekizumab drug product. The term device 
presentation refers to 2 different injection device presentations (bimekizumab -AI-1mL and 
bimekizumab -AI-2mL) that are comprised of drug product (IMP) associated with a functional 
secondary packaging.  
Bimekizumab will be supplied by [CONTACT_820219] a clear to 
opalescent, colorless to s lightly yellow -brown, sterile, preservative -free solution, suitable for 
injection by [CONTACT_820220], in either a 1mL prefilled syringe (PFS) or a 2mL PFS at a nominal 
concentration of 160mg/mL (55mM sodium acetate, 220mM glycine, 0.04% polysorbate 80 at  
pH 5.0) for sc administration.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 33 of 78 6.1 Treatments administered  
The treatments to be administered are presented in Table  6-1. 
Table  6-1: UP0119 treatments administered  
Study Treatment Name  [CONTACT_820241] -AI-2mL  Bimekizumab -AI-1mL  
Drug product:  2mL PFS  1mL PFS  
All treatments: a nominal formulation of 160mg/mL in 55mM 
sodium acetate, 220mM glycine and 0.04% (w/v) polysorbate 80 at 
pH5.0  
Total dose:  320mg  320mg  
Duration of treatment:  Single dose  Single dose  
Number of injections:  1x320mg  2x160mg  
Route of administration:  sc sc 
Site of injection:  Thigh (left or right)  Thigh (1 in left and 1 in right)  
Device:  2mL AI  1mL AI  
AI=auto -injector; PFS= prefilled syringe; sc=subcutaneous  
The IMP will be given in the thigh without massage. For bimekizumab -AI-1mL, the injection 
should continue until a second click is heard (to give an  injection time of up to 15  seconds). For 
the administration of the 2x1mL, each sc injection should be given in a separate thigh (but at the 
same relative site of the thigh) with a maximum time of [ADDRESS_1136881] timing of the inje ction(s) should be recorded in the electronic Case Report Form (eCRF). 
For bimekizumab -AI-2mL, the injection will take approximately up to [ADDRESS_1136882]. After the second click, continue to hold down the AI for an additional 
5 seconds to ensure the full dose is delivered.  
Further details on how to proceed in the event of malfunction of any of the devices will be 
provided in the IMP handling manual.  
6.1.1  Medical devices  
All medical device presentation deficiencies, including malfuncti on use error, and inadequate 
labelling, shall be  documented and reported by [CONTACT_346612] 
(see Section  8.3.7 ) and appropriat ely managed by [CONTACT_1034].  
[IP_ADDRESS]  Bimekizumab -AI-1mL 
The bimekizumab -AI-1mL is a single -use AI with a passive needle -safety mechanism. The 
bimekizumab -AI-1mL consists of a 1mL glass PFS containing bimekizumab drug product within 
a customized Ypsomed Ypsomate device. This device presentation was approved in the EU on 
20 Aug 2021.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 34 of 78 Figure  6-1: Bimekizumab -AI-1mL 
 
AI=auto -injector  
[IP_ADDRESS]  Bimekizumab -AI-2mL 
The bimekizumab -AI-2mL is a single -use AI with a passive needle -safety mechanism. The 
bimekizumab -AI-2mL consists of a 2.25mL glass PFS containing bimekizumab drug product 
within an Ypsomed Ypsomate device.  
Figure  6-2: Bimekizumab -AI-2mL 
 
AI=auto -injector  
6.[ADDRESS_1136883] be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the Investigator and authorized site 
staff.  
The Investigator, institution, o r the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  
In case an out -of-range temperature is noted, i t must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
Appropriate accountability forms that reflect the receipt and use of the IMP and the 
investigational device presentations including IMP will be supplied to the investi gational site. 
Details of any loss of the IMP and/or injection investigational device presentations due to 
breakage or wastage, non -use, destruction at the study site, or return to the Sponsor or designee 
must also be recorded on these forms. All supplies and pharmacy documentation must be made 
available throughout the study for UCB (or designee) to review.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
IMP and investigational device presentations until retu rned or destroyed. The Investigator may 
assign some of the Investigator’s duties for drug accountability at the study site to an appropriate 
pharmacist/designee.  
The device presentations should be stored with a proper study participant identification numbe r 
until the study has been completed. UCB will then instruct the Investigator to destroy them. Used 
device presentations can be stored at room temperature, preferably placed in the original 
packaging. Further details are provided in the IMP Handling Manual . 
The IMP and investigational device presentations intended for the study cannot be used for any 
other purpose than that described in this protocol.  
6.2.1  Retention samples  
As UP0119 is a BE study, retention samples are required to be kept at sites per FDA 
requi rement. All information related to storage and quantity needed on site will be provided in 
the IMP Handling Manual.  
6.3 Measures to minimize bias: randomization and blinding  
This is an open -label study.  
A PAREXEL Biostatistician (or designee) will write the ra ndomization plan, program and will 
provide a dummy output of the randomization lists for review and approval in order to ensure 
compliance to study requirements.  
Study participant treatment assignment will be random throughout the study. Study participants  
will be randomized in a 1:1 ratio to each treatment group as described in Section  4.1. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 36 of 78 Copi[INVESTIGATOR_188374]’s randomization list will be sent to the respective site before the start of the 
study to the following recipi[INVESTIGATOR_840]:  
• ClinBase TM setup designer  
• Sponsor Drug Safety staff for SAE reporting  
• Bioanalytical staff  
• Site pharmacist and Pharmaceutical Services staff (for dispensing IMP)  
Pharmacokinetic concentration data will not be available to the study team until after the last 
scheduled procedure for the last study participant in the study, so the decision to replace 
participants who dropped out or are missing PK visits can be made in an unbiased manner.  
At the Screening Visit, each study participant will be assigned a unique 5 -digit number from a 
range of numbers supplied by [CONTACT_305307] B. Once the Investigator determines that the study participant 
is eligible for the study, the study participant will be paired to another eligible study participant, 
matching by [CONTACT_820221] (≤10kg difference between the 2 participants) and manual ly 
assigned to the next 2 available randomization numbers by [CONTACT_820222] 1. Ideally, the participant’s body weight at admission (Day -1) should be used for 
pairing. Allocating in pairs will improve the precision of t he comparison between treatments. 
Each specific randomization number will identify the pair a study participant belongs to and is 
tied to the treatment allocation on the randomization schedule, which can then be dispensed by 
[CONTACT_7232]. This rando mization number will also be recorded in the eCRF (ie, ClinBase; 
see Section  10.1.6 ). 
Participants who withdraw from the study may be replaced at the discretion of the Investigator 
and Sponsor.  Any replacement must match the gender and weight (≤10kg difference  between the 
2 participants ) of the remaining participant being replaced and receive the same treatment as the 
participant being withdrawn from tr eatment.  
6.4 Treatment compliance  
All IMP will be administered by [CONTACT_21438]/her appropriately trained designee.  
6.5 Concomitant medication(s)/treatment(s)  
6.5.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following concomitant medicati ons are permitted during the study:  
• Acetaminophen/paracetamol (maximum 2g/day)  
• Oral contraceptives  
• Hormonal postmenopausal treatment  
• Herbal remedy or food supplements (eg, vitamins) within the recommended daily dose limits  
• Short -term intake of over -the-counter/non -prescription drugs is allowed if judged by [CONTACT_820223] -drug interactions with the IMP  
Non-live vaccines (eg, inactivated influenza and pneumococcal vaccines or non -live COVID 
vaccines) are allowed up to [ADDRESS_1136884] the UCB Study Physician or medically qualified 
designee/equivalent for further guidance.  
6.5.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
With the exception of those medications listed in Section  6.5.1  and medications necessary for the 
treatment of treatment -emergent adverse events (TEAEs) per Investigator discretion, no 
prescription or nonprescription medicines are allowed within 14 days (3 months for biologic 
agents) or 5 half -lives of the respective medication (whichever is longer), prior to randomization 
and until the SFU Visit (Day  140).  
6.6 Dose modification  
Not applicable.  
6.7 Treatment after the end of the study  
Not applicable.  
7 DISCONTINUATION OF S TUDY MEDICATION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1 Discontinuation of IMP  
Not applicable; eligible study participants are randomized to receive a single -dose administration 
of bimekizumab 320mg in UP0119.  
7.1.[ADDRESS_1136885] be discontinued or suspended for all 
remaining study participants who are yet to be dosed in the s tudy and appropriate follow -up 
procedures established for (but not limited to) any of the following reasons:  
• A pattern of adverse events (AEs), considered as related to the study drug, occurs that in the 
opi[INVESTIGATOR_3755]/or Sponsor Study Phy sician contraindicates the further dosing 
of additional study participants.  
• If the Sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations, and Good Clinical Practice (G CP). 
Where it is possible to do so without threatening the safety of study participants, such 
discontinuation/suspension should be discussed with the UCB Study Physician prior to its 
implementation.  
Study and site closure information is provided in Section  10.1.8 . 
7.2 Study participant withdrawal from the study  
Study participants are free to withdraw from the study at any time, without prejudice to their 
continued care and without having to provide any reason.  
A study participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administ rative reasons.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 38 of 78 If the study participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.  
If a study participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records.  
Upon study discontinuation, an Early WithdrawalVisit will be conducted at the time of 
withdrawal and the same assessments planned fo r the SFU Visit per the Schedule of activities 
(Section  1.3) will be performed.  
Study participants should be discontinued from the study if any of the following events occur:  
1. Study participant develops an illness that would interfere with his/her continued participation 
as per the Investigator’s judgment.  
2. Study participant is noncompliant with the study procedures in the opi[INVESTIGATOR_684].  
3. Study participant takes prohibited concomitant medications as defined in this protocol.  
4. Study participant withdraws his/her consent.  
5. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test. Study participants should  attend the SFU Visit following withdrawal . 
6. The Sponsor or a regulatory agency requests withdrawal of the study participant.  
7. Participation in any other study during the duration of this study.  
Study participants must be withdrawn by [CONTACT_820224]:  
• Any confirmed COVID -[ADDRESS_1136886] be taken if a study participant fails to return to the clinic for a 
required study visit:  
• The site must attempt to contact [CONTACT_820225] n whether or not the study participant wishes to and/or should 
continue in the study.  
• Before a study participant is deemed lost to follow up, the Investigator or designee must 
make a reasonable effort to regain contact [CONTACT_230188] (at least 1 phone call and 
1 written message to the study participant), and document his/her effort (date and summary 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 39 of 78 of the phone call and copy of the written message in the source documents), to complete the 
final evaluation . All results of these evaluations and o bservations, together with a narrative 
description of the reason(s) for removing the study participant, must be recorded in the 
source documents. The eCRF must document the primary reason for withdrawal or 
discontinuation.  
Should the study participant cont inue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow up documented in the eCRF.  
8 STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and their timing are summarized in the schedule of activ ities (Section  1.3). 
Protocol waivers or exemptions are not allowed.  
Adherence to the study design requirements, including those specified in the schedule of 
activities ( Section  1.3), is essential and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential study 
participants meet all eligibility criteri a. The Investigator will maintain a screening log to record 
details of all study participants screened and to confirm eligibility or record reasons for screening 
failure, as applicable.  
Procedures conducted as part of the study participant’s routine clinic al management (eg, blood 
count)  and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures met the protocol -specified criteria and were performed within the time 
frame defined in the schedule of activi ties. 
The maximum amount of blood collected from each study participant over the duration of the 
study, including any extra assessments that may be required, will not exceed 450mL. Repeat or 
unscheduled samples may be taken for safety reasons or for techni cal issues with the samples.  
8.1 Efficacy assessments  
Not applicable.  
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the schedule of activities 
(Section  1.3). 
8.2.1  Physical examination  
Physical examinations will be performed as per Section  1.3. The physical examination will 
include general appearance; ear, nose, and throat; eyes, hair, and skin; respi[INVESTIGATOR_696]; 
cardiovascular; gastrointestinal; musculoskeletal; hepatic; neurological ( including limb reflexes); 
and mental status. Findings considered as clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.  
A full physical examination will be performed at the Screening Visit, Day -1, and the 
EarlyWithdrawal/SFU Visit. On all other days a physical examination is planned, it will be 
performed symptom -driven (ie, in case of an AE).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 40 of 78 8.2.2  Body weight and height  
Body weight will be measured with the study participant wearing no shoes and light cl othing 
(weight should be recorded to one decimal place) according to the schedule of activities in 
Section  1.3. Height will only be measured at the Screening Visit.  
8.2.3  Vital signs  
Vital signs (BP [systolic and diastolic], pulse rate, and tympanic body temperature) will be 
recorded before taking PK samples and with the study participant resting in the supi[INVESTIGATOR_49844] 3  minutes  in a quiet sett ing without distractions (eg, television, cell phones). At 
outpatient visits without regular vital signs measurements, only tympanic body temperature will 
be collected. The number of readings to be collected will be determined by [CONTACT_820226] p rocedures (SOPs) at the sites.  
8.2.4  Electrocardiograms  
Single 12 -lead ECG will be obtained as outlined in the schedule of activities (see Section  1.3) 
using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, 
and QTc  intervals.  
All ECG recordings should be taken before taking PK samples and with the study participant 
resting in the supi[INVESTIGATOR_21683] 3 minutes.  
8.2.5  Clinical safety laboratory assessments  
See Appendix 2 (Section  10.2) for the list of clinical laboratory tests to be performed and the 
schedule of activities (Section  1.3) for the timing and frequency.  
Laboratory data will be electronically captured by [CONTACT_820227], a software tool that ensures quality 
assurance and enables comprehensive capture of all relevant medical information gathered 
during the study (Sec tion 10.1.6 ). The Investigator can assess the data in ClinBase and sign off 
on them electronically.  
All laboratory tests with values considered clinic ally significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_47998]. If such values do not 
return to normal /baseline within a period of time judged reasonable by [CONTACT_737], the 
etiology should be identified and the Sponsor notified.  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section  10.2), must be 
conducted in accordance with the laboratory manual and the schedule of activities (Section  1.3). 
If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are considered 
clinically significant by [CONTACT_737] (eg , SAE or AE), then the results are to be captured in 
ClinBase.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136887]  
Refer to g -q-100573, UCB Tuberculosis Detection Procedure Guideline for details regarding TB 
infection status, detection procedures, and the related exclusion criteria.  
A Quan tiFERON®-TB PLUS GOLD test and a TB questionnaire will be performed at the 
Screening Visit to identify those study participants who have had TB or may have active or latent 
TB. Results of this test will be reported as positive, negative, or indeterminate. Study participants 
with a positive test result will not be included in the study. If the result is reported as 
indeterminate, then the test can be repeated once. If the repeat test result is reported as 
indeterminate, then the study participant will not be  included in the study.  
8.3 Adverse events and serious adverse events  
The definitions of device -related safety events  (adverse device effects [ADEs] ) can be found in 
Appendix 7. Device deficiencies are addressed in Appendix 7 (Section  10.7). 
Adverse events will be reported by [CONTACT_87755] (or, when appropriate, by a caregiver, 
surrogate, or the study participant’s legally authorized representative).  
The Investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or study pro cedures, or that caused the 
study participant to discontinue the study  (see Section  7). 
Confirmed and suspected cases of SARS -CoV -2 infection will be  recorded as AEs (or SAE, as 
required).  
8.3.1  Time period and frequency for collecting AE and SAE information  
All AEs and SAEs will be collected from the signing of the ICF  and at the time points specified 
in the schedule of activities ( Section  1.3). 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretreatment and postt reatment periods required by [CONTACT_12695], must be reported in the CRF even if no study medication was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the initial visit and all AEs 
that recurred or worsened af ter the initial visit.  
All SAEs will be recorded and reported to the Sponsor  or designee within 24 hours, as indicated 
in Appendix 4 (Section  10.4). The Investigator will submit any updated SAE data to the Sponsor 
within [ADDRESS_1136888] and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they  are in no way associated with the IMP), up to 
[ADDRESS_1136889] be reported to UCB regardless of the 
time between the event and the end of the study.  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE re ports are provided in Appendix 3 (Section  10.3). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 42 of 78 8.3.2  Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the study participant is the preferred method to inquire about 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each study 
participant at subsequent visits/contacts. All SAEs, [and non -serious AEs of special interest (as 
defined in Section  8.3.6 ), will be followed until resolu tion, stabilization, the Investigator 
determines that it is no longer clinically significant, the event is otherwise explained, or the study 
participant is lost to follow up (as defined in Section  7.3). Further information on follow -up 
procedures is given in Appendix 3 (Section  10.3). 
8.3.[ADDRESS_1136890] be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Sponsor policy and forwarded to Investigators as 
necessary.  
An Investigator who receives an Investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it 
along with the IB and will notify the IEC, if appropriate according to local requirements.  
8.3.[ADDRESS_1136891] 
20 weeks after the administration of IMP (anticipated 5 half -lives) . 
If a pregnancy is reported, the Investigator must immediately inform the Sponsor within 24  hours 
of learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section  10.4). 
The study participant should be withdrawn from the study as soon as pregnancy is known (by 
[CONTACT_417712]), and the following should be completed:  
• The study participant should return for an early discontinuation visit.  
• A SFU Visit should be scheduled 20  weeks after the date of administration of the study 
participant’s IMP.  
Abnormal pregnancy outcomes (eg , spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pregnancy) are considered SAEs.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136892]/compound.  
For bimekizumab, the following event requires immediate reporting (within 24 hours, regardless 
of seriousness) to UCB:  
• Hy’s Law  
− Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality (ie, without waiting for any additional etiologic investigations 
to have been  concluded). Follow -up information should be reported if an alternative 
etiology is identified during investigation and monitoring of the study participant.  
[IP_ADDRESS]  Other safety topi[INVESTIGATOR_786791]: infection s (serious, opportunistic, fungal 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, major cardiovascular 
events, liver function test changes/enzyme elevations, malignancies, and inflammatory bowel 
diseases (with gastroenterology refer ral, as appropriate).  
This is based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or findings from other medicines with a related 
mechanism of action. There are no specific AE report ing requirements for these topi[INVESTIGATOR_1102]; however, 
special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB) are in place.  
8.3.7  Medical device – adverse device effects and device presentation 
deficiencies  
Medical device presentations are being provided for use in this study. In order to fulfill 
regulatory reporting obligations worldwide, the Investigator is responsible for the detection and 
documentation of events meeting the definitions of device deficienc y that occur during the study 
with such device presentations.  
Adverse events will be reported according to the ISO [ZIP_CODE]:2020, while recognizing and 
following requirements including reporting timelines specified in other specific laws, 
regulations, directi ves, standards and/or guidelines as appropriate and as required by [CONTACT_368817].  
The definition of a device deficiency can be found in Appendix 7 (Section  10.7). 
[IP_ADDRESS]  Time period for detecting medical device presentation deficiencies  
Device deficiencies or malfunctions of the device presentation that result in reportable events 
will be detected, documented, and reported on the date of IMP administration when the medical 
device presentation is used.  
The method of documenting Medical Device Deficiency is provided in Appendix  7. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 44 of 78 [IP_ADDRESS]  Follow -up of device deficiencies  
Follow -up applies to all study participants, including those who discontinue the study.  
The Investigator is responsible for ensuring that follow up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the deficiency.  
New or updated information will be recorded on th e originally completed form with all changes 
signed and dated by [CONTACT_737].  
[IP_ADDRESS]  Prompt reporting of device deficiencies to the Sponsor  
Device deficiencies will be reported to the Sponsor within [ADDRESS_1136893] for the receipt of medical device deficiency reports.  
[IP_ADDRESS]  Regulatory re porting requirements for device deficiencies  
The Investigator will promptly report all device deficiencies occurring with any medical device 
presentation used in the study in order for the Sponsor to fulfill the legal responsibility to notify 
appropriate r egulatory authorities and other entities about certain safety information relating to 
medical device presentations being used in clinical studies.  
The Investigator, or responsible person according to local requirements (eg, the head of the 
medical institut ion), will comply with the applicable local regulatory requirements relating to the 
reporting of device deficiencies to the IEC.  
8.[ADDRESS_1136894] as early as possible any 
safety c oncern(s) related to the IMP and/or device presentation so that Investigators, clinical 
study participants, regulatory authorities, and IECs will be informed appropriately and as early as 
possible.  
The UCB Study Physician or medically qualified designee/eq uivalent will conduct an ongoing 
review of SAEs and perform ongoing SAE reconciliations in collaboration with the Patient 
Safety representative.  
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified person nel at UCB may identify additional safety measures (eg,  AEs, vital 
signs, laboratory, or ECG results) for which data will be periodically reviewed during the course 
of the study.  
8.5 Treatment of overdose  
For this study, any dose of bimekizumab greater than a single -dose administration of 320mg will 
be considered an overdose. Overdose events are only considered AEs or SAEs if there are 
associated clinical signs and symptoms.  
8.6 Pharmacokinetics  
Whole blood samples will be collected for measurement of plasma concen trations of 
bimekizumab as specified in the schedule of activities (Section  1.3). Instructions for the 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 45 of 78 collection and handling of biological samples will be provided by [CONTACT_1034]. The actual date 
and time (24 -hour clock time) of each sample will be recorded. The overall blood volume to be 
drawn from each study participant participating in the study will not exceed 450mL, ie, the 
amount of a blood don ation.  
Samples will be used to evaluate the PK of bimekizumab.  
Genetic analyses will not be performed on these blood samples. Study participant confidentiality 
will be maintained. At visits during which blood samples for the determination of multiple 
aspec ts of bimekizumab will be taken, one  sample of sufficient volume can be used.  
All PK samples should be drawn from study participants after the ECG has been recorded and 
the vital signs, including BP, have been measured. The following PK parameters will be derived 
from the plasma concentrations of bimekizumab:  
• Area under the plasma concentration -time curve from time zero to infinity (AUC)  
• Area under the plasma concentration -time curve from time zero to the last quantifiable 
concentration (AUC [0-t]) 
• Maximum o bserved plasma drug concentration (C max) 
• Time of occurrence of C max (tmax) 
• Apparent terminal half -life (t ½) 
• Apparent total body clearance (CL/F) after sc administration , calculated as dose/AUC  
• Apparent volume of distribution (V z/F), calculated as CL/λz  
• Percentage of the AUC extrapolated from the last observed quantifiable plasma drug 
concentration  (Clast) (%AUC ex) 
All PK data analyses will be performed under the supervision of the Quantitative Clinical 
Pharmacology Department, UCB using validated softwar e (Phoenix 64, Pharsight, a Certara 
Company, [LOCATION_003]).  
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by [CONTACT_820228] s, but will not constitute a protocol amendment. The IEC will be informed of 
any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF. 
Pharmacokinetic samples for concentration measurement of bimekizumab may be stor ed for a 
maximum of 5 years (or according to local regulations) following the last study participant’s last 
visit at a facility selected by [CONTACT_1034].  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Pharmacodynamics  
Pharmacodynamic parameters  are not evaluated in this study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 46 of 78 8.9 Biomarkers  
Biomarkers are not evaluated in this study.  
8.10 Immunogenicity assessments  
Antibodies to bimekizumab will be evaluated in plasma samples collected from all study 
participants according to the schedule of activities (Section  1.3). If feasible, additional blood 
samples for PK and anti -drug antibody (ADAb) analysis should be collected from participants 
who develop a hyperse nsitivity reaction. This sample should be obtained close to the time of the 
event using an unscheduled visit if needed. Additionally, plasma samples should also be 
collected at the final visit from study participants who were withdrawn from the study. Thes e 
samples will be tested by [CONTACT_13679]’s designee.  
Plasma samples will be screened for antibodies binding to bimekizumab and the titer of 
confirmed positive samples will be reported. Other analyses may be performed to verify the 
stability of an tibodies to bimekizumab and/or further characterize the immunogenicity of 
bimekizumab . 
The detection and characterization of antibodies to  bimekizumab will be performed using a 
validated assay method by [CONTACT_23788]. Anti -drug-antibodies will be 
measured using a three -tiered assay approach: screening assay, confirmatory assay, and titration 
assay.  Samples may be stored for a maximum of 5 years (or according to local regulations) 
following the last study participant’s last visit fo r the study at a facility selected by [CONTACT_820229].  
8.11 Medical resource utilization and health economics  
Not applicable.  
9 STATISTICAL CONSIDER ATIONS  
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP).  
9.[ADDRESS_1136895] of all randomized study participants. Not e: This set will only be 
produced if it differs from the Safety Set.  
The Safety Set will consist of all study participants who are randomized and receive full or 
partial IMP according to the treatment the participants actually received. The Safety Set will  be 
used for summaries of demographics, medical history, prior and concomitant medications, IMP 
exposure, and general safety outcomes such as AEs, laboratory parameters, vital signs, and 
ECGs.  
The Pharmacokinetic Set (PKS) will be a subset of the Safety Se t, consisting of those study 
participants that received at least [ADDRESS_1136896] obser ved concentrations will be included in summary tables and 
figures of concentration -time profiles and PK parameters.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 47 of 78 9.2 General statistical considerations  
All analyses will be performed using Statistical Analysis System® (SAS®) version 9.4 or later 
(SAS Instit ute, Cary, NC, [LOCATION_003]).  
For continuous variables, summary statistics will include number of study participants, mean, 
median, standard deviation (SD), minimum, and maximum. Categorical endpoints will be 
summarized using number of study participants, frequency , and percentages. Missing data will 
not be imputed.  
If not otherwise stated, Baseline will be the last assessment prior to dosing. Measurement of 
specific Baseline values will be described in the SAP.  
9.3 Planned efficacy/outcome analyses  
As efficacy is not evaluated in this study, there is no primary efficacy endpoint.  
9.4 Planned outcome analyses  
9.4.1  Primary endpoint analyses  
The PK analyses will be performed on the PKS.  
Following log e-transformation, the primary PK parameters (C max, area under the plasma 
concentra tion-time curve from time zero to the last quantifiable concentration  [AUC (0-t)], and 
AUC) will each be evaluated according to an analysis of variance (ANOVA) model with a fixed 
effect term for pair and treatment. The estimate of the ratio of geometric mea n for the AI -2mL 
(test) versus 2xbimekizumab -AI-1mL (reference) treatment along with the associated 90% 
confidence intervals (CIs) for the ratio will be calculated. Bioequivalence will be concluded if 
the 90% CIs for the ratio of the comparison is fully in cluded in the acceptance range from 0.8 to 
1.25 for AUC, AUC (0-t), and C max. 
Two sensitivity analyses will add 1) the main effect of center and 2) both main effect of center 
and center -by-treatment interaction. Further sensitivity analyses may also be perf ormed on the 
PK parameters.  
9.4.2  Secondary endpoint analyses  
Additionally, a similar ANOVA will be also performed on log e-transformed t½ to compare 
elimination characteristics between treatment groups. The point estimate and the 90% CI for the 
median treatment differences for t max will be computed according to the Hodges Lehmann’s 
method.  
9.5 Planned safety and other analyses  
9.5.1  Safety analyses  
All safety parameters will be listed by [CONTACT_820230].  
The incidence of TEAEs will be determined by [CONTACT_1570], where applicable. Absolute and 
relative frequencies for a given TEAE by [CONTACT_820231] (MedDRA®, version 19.0) will be determined within each treatment group 
and system organ class. Additional tables will summarize TEAEs by [CONTACT_820232]. The actions taken for each 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136897] to QT/QTc. Descriptive statistics will be presented 
for ECG value and changes  from Baseline over time.  
Descriptive statistics will be reported for all vital sign measurements (including systolic and 
diastolic BP, pulse rate, and tympanic body temperature). Measured values and changes from 
Baseline will be summarized for all study p articipants by [CONTACT_7206].  
Abnormal findings in the physical examination will be presented in listings only.  
9.5.2  Immunogenicity analyses  
Bimekizumab ADAb levels will be listed per participant and summarized using summary tables 
and figures. The number (and per centage) of study participants with first occurrence of 
treatment -induced ADAb positivity will also be summarized at each postdose visit.  
9.5.3  Other analyses  
[IP_ADDRESS]  Study participant disposition and characteristics  
The number of study participants who were enrolled an d randomized into the study, in each 
analysis set, and who completed or prematurely discontinued the study, as well as the reason for 
discontinuation, will be presented by [CONTACT_669009]. In addition, listings will be provided for study discontinuation, study participant 
disposition, and participant analysis sets.  
Study participant characteristics will include a summary and listing of the following:  
• Demographics (including sex, age, race, ethnicity, height, weig ht, BMI, and lifestyle)  
• Medical history  
• Prior and concomitant medications  
Concomitant medical procedures will only be listed.  
9.[ADDRESS_1136898].  
Important protocol deviations are identified as part of the data cleaning process in the Data 
Cleaning Plan (DCP). The objective of the data cleaning meeting will be to review and update (if 
necessary) the important protocol deviations in the DCP and discu ss exclusion of study 
participants from analysis populations.  
Furthermore, overall trends in protocol deviations will be discussed at the Data Evaluation 
Meeting. Through this data cleaning and evaluation process, all decisions regarding important 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 49 of 78 protocol  deviations and exclusions from analysis populations will be made. Protocol deviations 
(eg, missing assessments or visits) related to COVID -19 may be listed separately.  
Accepted deviations from theoretical time points will be described in the appropriate d ocuments 
and included in the trial master file (TMF).  
After resolution of all issues, and documentation of all decisions, the database will be locked.  
9.7 Handling of dropouts or missing data  
There will be no special procedures for handling missing data. All i mputation of missing or 
partial dates for safety assessments, as well as handling values below the limit of quantification 
in the PK data, will be detailed in the SAP.  
9.8 Planned interim analysis and data monitoring  
No formal interim analysis is planned for t his study.  
9.9 Determination of sample size  
This is a BE study to compare the PK of bimekizumab -AI-2mL (test) versus bimekizumab -AI-
1mL (reference).  
The sample size estimation was based upon variability observed in studies UP0033 and UP0068. 
These were the [ADDRESS_1136899] recent studies which included the AI device with a single administration 
of bimekizumab in healthy study participants. The respective inter -participant variabilities 
(coefficient of variation [CV%]) observed in these studies were up to 32%, 33% (AUC) a nd 
31%, 25% (C max). The geometric mean ratios for all primary PK parameters were between 0.97 
and 1.02 (UP0033) and between 1.03 and 1.15 (UP0068). The individual study CV% and 
geometric mean ratios are presented in Appendix 11 (Section  10.11 ). 
Assuming a geometric mean ratio of 1.08 (or 0.93) and inter -participant variability (CV%) of 
32%, 54 study participants per group are required to assess BE with 80% power assuming that 
BE will be declared if the 90% CI for the geometric mean ratio is conta ined entirely within the 
acceptance range (0.8, 1.25).  
Sample size estimation was performed using SAS software (version 9.4).  
Assuming a dropout rate and non -evaluable study participants of approximately 10%, 60 study 
participants per group for a total of approximately 120 study participants are to be enrolled in the 
study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 50 of 78 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, ethical, and study oversight 
considerations  
10.1.1  Regulatory and ethical considerations  
The study will be conduc ted under the auspi[INVESTIGATOR_820200], as defined in local regulations, 
International Council for Harmonisation (ICH) -GCP (ICH E6[R2]), and in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki (1996).  
The Investigator/ UCB will ensure that an appropriately constituted IEC that complies with the 
requirements of the current ICH -GCP version or applicable country -specific regulations will be 
responsible for the initial and continuing review and approval of the clinical study . Prior to 
initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_18280], ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other study 
participant -related documents to be used for the stud y to the IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IEC for the protocol.  
The Investigator will also promptly report to the IEC all changes in the study, all u nanticipated 
problems involving risks to study participants or others, and any protocol deviations, to eliminate 
immediate hazards to study participants.  
The Investigator will not make any changes in the study or study conduct without IEC approval, 
except where necessary to eliminate apparent immediate hazards to the study participants. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for the Investigator to obtain an expedited review  by [CONTACT_820233].  
As part of the IEC requirements for continuing review of approved studies, the Investigator will 
be responsible for submitting periodic progress reports to the IEC (based on IEC requirements), 
at intervals appropriate to the degree of study participant risk involved, but no less than once per 
year. The Investigator should provide a final report to the IEC following study completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IEC will also be informed by [CONTACT_29539], as specified by [CONTACT_122299]. Where applicable, Investigators 
are to provide the Sponsor (or its representative) with evidence of any such IEC notification.  
10.1.2  Financial disclosure  
Insurance coverage will be handled according to local requirements.  
Finance and insurance are addressed in t he Investigator and/or CRO agreements, as applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 51 of 78 10.1.3  Informed consent process  
Study participant’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origi n in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the study participant in both oral and written form by [CONTACT_3786] (or de signee). Each study participant will have the opportunity to discuss the study 
and its alternatives with the Investigator.  
Prior to participation in the study, an IEC -approved, written ICF should be signed and personally 
dated by [CONTACT_820234] 
(Investigator or designee) prior to the initiation of any study -specific assessment at the Screening 
Visit. The study participant must receive a copy of the signed and dated ICF. As part of the 
consent process, each study participant must consent to direct access to his/her medical records 
for study -related monitoring, auditing, IEC review, and regulatory inspection.  
If the ICF is amended during the study, the Investigator (or the Sponsor, if appli cable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
[CONTACT_820235].  
The study participant may withdraw his/her consent to participate in the study at any time. A 
study participant is considered as enrolled in the study when he/she has signed the ICF. An eCRF 
must not be started, nor may any study specific procedure be performed for a given study 
participant, without having obtained his/her written consent to participate in the study . 
10.1.4  Data protection  
UCB staff (or designee) will affirm and uphold the study participant’s confidentiality. 
Throughout this study, all data forwarded to UCB (or designee) will be identified by [CONTACT_114812]’s randomization number.  
The Investigator ag rees that representatives of UCB, its designee, representatives of the relevant 
IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
study participant’s primary medical records that directly concerns this study (i ncluding, but not 
limited to, laboratory test result reports, ECG reports, admission/discharge summaries for 
hospi[INVESTIGATOR_1684] a participant’s study participation, and autopsy reports for 
deaths occurring during the study).  
The study par ticipant must be informed that his/her personal study -related data will be used by 
[CONTACT_9324]. The level of disclosure must also be 
explained to the study participant.  
The study participant must be informed tha t his/her medical records may be examined by 
[CONTACT_9325], by 
[CONTACT_820236], and by [CONTACT_6668].  
10.1.[ADDRESS_1136900] access to all records 
necessary to ensure the integrity of the data and will periodically review the progress of the study 
with the  Investigators. Remote monitoring visits may be conducted during the COVID -19 
pandemic or under other exceptional circumstances as deemed appropriate to ensure study 
participants’ safety.  
The Investigator must permit study -related monitoring, audits, IEC r eview, and regulatory 
agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
Study Monitors will perform ongoing source dat a verification to confirm that data entered into 
ClinBase by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in ac cordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
All essential documents are to be retained by [CONTACT_31201] [ADDRESS_1136901] elapsed since the 
formal discontinuation of clinical development of the IMP/investigational device. These 
document s should be retained for a longer period, however, if required by [CONTACT_40006](s) or by [CONTACT_18415] (CPMP/ICH/135/95, 2002 
[Section  4.9.5]). The Investigator will contact [CONTACT_352271]. The 
Investigator will also notify UCB should he/she relocate or move the study -related files to a 
location other than that specified in the Sponsor’s TMF.  
[IP_ADDRESS]  Case Report  form completion  
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in 
ClinBase and in all required reports.  
Any change or correction to ClinBase after saving must be accompanied by a reason for the 
change.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 53 of 78 Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be reapproved by [CONTACT_737].  
The Investigator should maintain a list of personnel authorized to enter data into ClinBase.  
[IP_ADDRESS]  Apps  
Not applic able.  
10.1.[ADDRESS_1136902] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent for m of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] 
(such as removable self -stick notes).  
Source documents are original records in which raw data are first recorded. These may include 
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.  
Source documents that are computer generated and stored electronically must be printed for 
review by [CONTACT_2037] (eg,  ECG reports). Once printed, these copi[INVESTIGATOR_820201] a nd become a permanent part of the study participant’s source documents.  
If source documents have been captured by [CONTACT_820227], they need to be electronically 
signed/stamped to indicate review by [CONTACT_737]/designee/delegate.  
The Investigator/designee wi ll facilitate the process for enabling the monitor to compare the 
content of the printout and the data stored in the computer to ensure all data are consistent.  
10.1.[ADDRESS_1136903] been collected and a study -site closure  visit has been performed.  
The Investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_9330]:  
• Failure of the Investigator to comply with the protocol, the requirements of the IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines  
• Inadequate recruitment of study participants b y the Investigator  
• Discontinuation of further IMP development  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 54 of 78 • A required adaptation of the maximum insurance sum is not possible (ie, the risk/benefit 
estimation changes, leading to insufficient insurance coverage while the maximum insurance 
sum is not ada pted)  
• The positive evaluation or approval is withdrawn by [CONTACT_820237]  7.1.[ADDRESS_1136904] editorial and ethical practice, the Sponsor will generally support publication of 
multicen ter studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_820238].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 55 of 78 10.2 Appendix 2: Clinical laboratory tests  
The tests detailed in Table  10-1 below will be performed. The following central laboratories will 
be used:  
• For the site in [LOCATION_013]: at SGS Analytics [LOCATION_013] GmbH (safety laboratory assessments) 
and Parexel International (urinalysis/urine drug screen and SARS -CoV -2 RT -PCR).  
• For the site in the US: at Parexel International (urine drug screen, in -house pregnancy) and 
GenX Laboratories, Inc. (safety laboratory assessments and everything else required).  
Protocol -specific requi rements for inclusion or exclusion of study participants are detailed in 
Section  5.1 and Section  5.2 of this protocol.  
Additional tests may be performed at any time during the study as determined necessary by [CONTACT_56861].  
Table  10-1: Protocol -required safety laboratory assessments  
Laboratory measurements  Variables  
Serology  HbsAg, HBc -Ab (both IgG and IgM), HCV -Ab, HIV1 -Ab, 
HIV1 -Ag, HIV -2 Ab , SARS -CoV -2 RT -PCRa 
Hematology  Complete blood count, ie, hemoglobin, hematocrit, RBC, 
WBC, WBC with differential, platelet count  
Coagulation/hemostasis  Prothrombin time, aPTT  
Clinical chemistry  Albumin, ALP, ALT, AST, GGT, creatine kinase, LDH, total 
bilirubin, BUN, creatin ine, glucose, total cholesterol, LDL 
cholesterol, HDL cholesterol, triglycerides, electrolytes 
(sodium, potassium, chloride, total calcium), and total 
protein, FSH  
Urine (dipstick) b pH, protein, glucose, ketone, urobilinogen, bilirubin, blood, 
specific g ravity, nitrite, and leukocytes  
Urine alcohol test/drug screen  Ethanol will be measured using a urine alcohol test.  
Urine drug screen includes 
amphetamines/methamphetamines, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], tetrahydrocannabinol, cocaine, tricyclic 
antidepre ssants, phencyclidine, and morphine/opi[INVESTIGATOR_820202], a serum pregnancy test (hCG) will be 
performed; post dosing the test may be performed in urine.  
The FSH test will be performed in postmenopausal women at 
the Screening Visit.  
ALP=alka line phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle stimulating hormone; 
GGT=gamma  glutamyltransferase; HBc -Ab=hepatitis B core antibody; HbsAg=he patitis B surface antigen; 
hCG=human chorionic gonadotropin; HCV -Ab=hepatitis C virus antibody; HDL=high density lipoprotein; 
HIV=human immunodeficiency virus; HIV1/2 -Ab=HIV1/2 antibody; HIV1 -Ag=HIV1 antigen; LDH=lactate 
dehydrogenase; LDL=low density lipo protein; RBC=red blood cell; WBC=white blood cell  
a Sample will be obtained per local requirements.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136905] for leukocytes, blood, nitrite, or protein, the Investigator may require further urine 
analysis, such as flow cytometry. Results of additional urine analyses will be included in the database. If the flow 
cytometry examination shows a different result than the urine dipsticks, the urine will be investigated by [CONTACT_820239], erythrocytes, an d casts (cellular, granular, hyaline) in urine will be 
analyzed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 57 of 78 10.3 Appendix 3: Adverse events – definitions and procedures for 
recording, evaluating, follow up, and reporting  
10.3.1  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patie nt or clinical study participant, temporally 
associated with the use of IMP, whether or not considered related to the IMP.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new  or exacerbated) temporally associated with the 
use of IMP.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after IMP administration even though it may have been 
present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either IMP or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with po ssible suicidal/self -harming intent. Such overdoses should be 
reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by [CONTACT_820240]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the study participant’s 
condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condi tion that leads to the 
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 58 of 78 10.3.2  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due t o 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term ‘life -threatening’ in the definition of ‘serious’ refers to an event in which the study participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically might 
have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_820203] (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would 
not have been appropriate in the physician’s office or outpatient setting. Complica tions that occur 
during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_40030], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, 
the AE should be considered s erious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from Baseline is 
not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to c onduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) which may interf ere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical events:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_228057] t he study participant or 
may require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious.  
• Examples of such events include, but are not limited to, potential Hy’s law, invasive or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], or 
development of drug dependency or drug abuse.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 59 of 78 10.3.3  Recording and follow up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related 
to the event.  
• The Investigator will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_820204]’s medical 
records to UCB in lieu of completion of the UCB AE/SAE eCRF page.  
• There may be insta nces when copi[INVESTIGATOR_368744]. In this case, all study participant identifiers, with the exception of the study participant 
number, will be redacted on the copi[INVESTIGATOR_368745].  
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensit y 
The Investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_87755], causing minimal discomfort and 
not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused wi th a SAE. Severe is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NO T when it is rated as severe (eg, a severe AE may be 
either serious or not serious, depending on whether these criteria are also met).  
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI -CTCAE) 
should be used as a supportive s tandardization instrument to evaluate AEs and SAEs but the final 
intensity grading by [CONTACT_671437], moderate, or severe.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 60 of 78 Assessment of Causality  
• The Investigator is obligated to assess the relationship between IMP and each occurrence of  
each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator will use clinical judgment to determine t he relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to IMP administration will be considered and 
investigated.  
• The Investigator will also consult  the IB and/or Product Information, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of  the SAE data to UCB . 
• The Investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining re gulatory reporting 
requirements.  
 
Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_368819]/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with other 
health care professionals.  
• An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the study participant is lost to follow up. 
This follow -up requirement applies to AEs, SAEs, and AEs of speci al interest.  
• If a study participant dies during participation in the study or during a recognized follow -up 
period, the Investigator will provide UCB  with a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recor ded in the originally completed eCRF.  
• The Investigator will submit any updated SAE data to the UCB within 24 hours of receipt of 
the information.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 61 of 78 Reporting of SAEs  
SAE Reporting to UCB via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to UCB will be the electronic data collection 
tool. 
• If the electronic system is unavailable for more than 24 hours, then the site will use the paper 
SAE data collection tool (see next section).  
• The site will enter the SAE data into the ele ctronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off -
line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off -line, then 
the site can report this information on a paper SAE form (see next bullet) or to the  UCB Study 
Physician  by [CONTACT_756].  
• Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 62 of 78 10.4 Appendix 4: Contraceptive guidance and collection of 
pregnancy information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woma n is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered WOCBP : 
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
− Documented hysterectomy  
− Documented bilateral salpi[INVESTIGATOR_1656]  
− Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel’s review of the study participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
− A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
− Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non -estrogen hormon al highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
Contraception Guidance  
Male study  participants  
Male study participants with female partners of childbearing potential are eligible to participate 
if they agree to ONE of the following for a period of 20 weeks after their dose of IMP.  
• Are abstinent from penile -vaginal intercourse as their usual and preferred  lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent.  
• Agree to use a male condom plus partner use of a contraceptive method with a failure rate of 
<1% per year as described in Appendix 4 (Section  10.4) when having penile -vaginal 
intercourse with a woman of childbearing potential  who is not currently pregnant.  
In addition, male study participants must refrain from do nating sperm for the duration of the 
study and for at least [ADDRESS_1136906] agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_47960] -defined time frame.  
Female study participants  
Female study participants of childbearing potential are eligible to participate if they agree to use 
a highly effective method of contraception consistently and  correctly as described in Appendix 4 
(Section  10.4). 
Table  10-2: Highly effective contraceptive methods a 
Highly Effective Contraceptive Methods That Are User Dependentb 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulation  
• Oral 
• Intravaginal  
• Transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation  
• Oral 
• Injectable  
Highly Effective Methods That Are User Independentb 
Implantable progestogen -only hormonal contraception associated with inhibition of ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the woman of childbearing potential ( WOCBP) and the absence of sperm has 
been confirmed. If not, an additional highly effective m ethod of contraception should be used.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the IMP. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and 
usual lifestyle of the study participant.  
a In case of newly started contraception pi[INVESTIGATOR_3353]/IUDs, PI [INVESTIGATOR_671346]/applying s uch 
methods in relation to the menstrual cycle and the manufacturing instruction as when these newly started methods 
would become effective.  
b Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for study participants participating in clinical 
studies.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 64 of 78 Pregnancy testing  
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive serum pregnancy test. 
• Additional pregnancy testing should be performed at monthly intervals during the treatment 
period, and at the SFU Visit at Day 140.  
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
• Pregnancy testing, with a sensitivity of 25mIU/mL will be performed.  
Male participants with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male study 
participant’s female partner who becomes pregnant while t he male study participant is in this 
study and for at least 20 weeks after IMP administration . 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the approp riate form and 
submit it to the Sponsor within 1 working day of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow 
up will be at least 12 months after the delivery date. Any termination of the pregnancy will 
be reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
Female participants w ho become pregnant  
• Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study.  
• The Investigator will collect pregnancy information on any female study participant who 
becomes pregnant while participating i n this study. Information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours  of learning of a study 
participant’s pregnancy. The study participant will be followed to determine the outcome of 
the pregnancy. The Investigat or will collect follow -up information on the study participant 
and the neonate and the information will be forwarded to the Sponsor. Generally, the follow 
up will be at least 12 months after the delivery date. Any termination of pregnancy will be 
reported,  regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE.  A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy -related SAE considered reasonably related to the IMP by [CONTACT_149576]  8.3.5 . While the Investigator is not obligated 
to actively seek this information in former study participants, he or she may learn of an SAE 
through spontaneous re porting.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 65 of 78 10.5 Appendix 5: Genetics  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 66 of 78 10.6 Appendix 6: Liver safety – suggested actions and follow -up 
assessments  
Study participants with potential drug -induced liver injury should not be withdrawn from the 
study until investigation and monitoring are c omplete. All results of these evaluations and 
observations, as well as the reason(s) for study participant withdrawal (if applicable), must be 
recorded in the source documents.  
A specific monitoring plan must be agreed between the UCB Study Physician and t he 
Investigator for study participants who have ALT >[ADDRESS_1136907]. The monitoring plan should include 
any necessary follow -up assessments (until resolution of the abnormal lab values).  
Phase 1 liver chemistry stoppi[INVESTIGATOR_820205] ( Table  10-3). 
Table  10-3: Phase I liver chemistry stoppi[INVESTIGATOR_377035] -up 
assessments  
Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_42250] -absolute  ALT≥3xULN  
If ALT ≥3xULN AND bilirubin 2xULN (>35% direct bilirubin) OR 
international normalized ratio (INR) >1.5, report as a serious adverse event 
(SAE).a,b 
See additional actions and follow -up assessments listed below.  
Suggested Actions and Follow up Assessments  
Actions  Follow Up Assessments  
• Report the event to the UCB within 24 hours  
• Complete the liver event eCRF, and complete 
an SAE data collection tool if the event also 
met the criteria for an SAE.  
• Perform liver chemistry follow -up assessments.  
• Monitor the study participant until liver 
chemistry test abnormalities resolve, stabilize, 
or retu rn to Baseline (see MONITORING).  
MONITORING:  
If ALT 3xULN AND bilirubin 2xULN or INR 
>1.5:  
• Repeat liver chemistry tests (include ALT, 
AST, ALP, bilirubin) and perform liver event 
follow -up assessments within 24 hours.  
• Monitor study participant twice week ly until 
liver chemistry test abnormalities resolve, 
stabilize, or return to Baseline.  • Viral hepatitis serologyc 
• Obtain INR and recheck with each 
liver chemi stry assessment until the 
transaminases values show 
downward trend  
• Serum creatine phosphokinase and 
LDH  
• Fractionate bilirubin, if total 
bilirubin 2xULN  
• Obtain complete blood count with 
differential to assess eosinophilia  
• Record the appearance or worsening  
of clinical symptoms of liver injury, 
or hypersensitivity, on the AE eCRF  
• Record use of concomitant 
medications (including 
acetaminophen, herbal remedies, and 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 67 of 78 Table  10-3: Phase I liver chemistry stoppi[INVESTIGATOR_377035] -up 
assessments  
Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_53056]  
• A specialist or hepatology consultation is 
recommended.  
If ALT ≥3xULN AND bilirubin <2xULN and INR 
≤1.5:  
• Repeat liver chemistry tests (include ALT, 
AST, ALP, bilirubin) and perform liver 
chemistry follow -up assessments within 24 to 
72 hours.  
• Monitor study participants weekly until liver 
chemistry abnormalities resolve, stabilize, or 
return to Baseline.  other over -the-counter medications) 
on the concomitant medications 
eCRF  
• Record alcohol use on th e liver event 
alcohol intake eCRF  
If ALT ≥3xULN AND bilirubin 
2xULN or INR >1.5:  
• Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti -liver 
kidney microsomal antibodies, and 
quantitative total IgG or gamma 
globulins  
• Serum acetaminophen adduct high 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver 
injury in study participants with 
definite or likely acetaminophen use 
in the preceding week [James, 
2009])  
• Liver imagi ng (ultrasound, magnetic 
resonance, or computerized 
tomography) and/or liver biopsy to 
evaluate liver disease; complete liver 
imaging and/or liver biopsy eCRFs  
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin  fractionation testing is 
unavailable, record the absence/presence of detectable urinary bilirubin on dipstick, which is indicative of direct 
bilirubin elevations suggesting liver injury.  
b All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirub in) or ALT ≥3xULN and INR >1.5 may 
indicate severe liver injury (possible ‘Hy’s Law’) and must be reported as SAEs (excluding studies of hepatic 
impairment or cirrhosis). The INR measurement is not required and the stated threshold value will not apply to 
study participants receiving anticoagulants.  
c Hepatitis A immunoglobulin M (IgM) antibody; HbsAg and HbcAb; hepatitis C ribonucleic acid; cytomegalovirus 
IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, heterophile antibody  or monospot 
testing); and hepatitis E IgM antibody.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 68 of 78 10.7 Appendix 7: Medical device presentation ADEs and Device 
Deficiencies:  – definition and procedures for recording, 
evaluating, follow up, and reporting  
10.7.1  Definitions of a medical device presentation incident  
The definitions and procedures detailed in this appendix are in accordance with ISO [ZIP_CODE].  
Both the Investigator and the sponsor will comply with all local medical device reporting 
requirements.  
The detection and documentation procedures described in this  protocol apply to all Sponsor 
medical device presentations provided for use in the study. See Section  6.1.1  for the Sponsor 
medical device presentatio ns. 
10.7.2  Definition of ADE  
AE and ADE Definition  
• An ADE is defined as an adverse event related to the use of an investigational medical device. 
This definition includes any adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction of 
the investigational medical device as well as any event resulting from use error or from 
intentional misuse of the investigational medical device.  
10.7.3  Definition of device deficiency  
Device deficiency definition  
• A device presentation deficiency is an inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, safety, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate  labeling.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 69 of 78 10.7.4  Recording and follow up of ADE and device deficiencies  
ADE and device deficiency recording  
• When an ADE /device deficiency occurs, it is the responsibility of the Investigator to review 
all documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant ADE /device deficiency information in the 
participant’s medical records, in accordance with the Investigator’s normal clinical practice 
and on  the appropriate form of the CRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical records 
to UCB in lieu of completion of the UCB ADE/ device deficiency CRF page.  
• There may be instances when copi[INVESTIGATOR_820206]. In this case, all participant identifiers, with the exception of the participant number, will 
be redacted on the copi[INVESTIGATOR_368745].  
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the ADE.  
• For device deficiencies, it is very important that the Investigator re turns the device to the 
sponsor, and describes any corrective or remedial actions taken to prevent recurrence of the 
deficiency.  
o A remedial action is any action other than routine maintenance or servicing of a 
medical device where such action is necessary to prevent recurrence of a device 
deficiency. This includes any amendment to the device design to prevent recurrence. 
The Investigator should complete a Product Complaint Form for all reported device 
deficiencies.  
Assessment of intensity  
The Investigator  will make an assessment of intensity for each ADE /device deficiency reported during 
the study and assign it to one of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and not 
interfering wit h everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with a SAE. Sever e is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is ra ted as severe.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 70 of 78 Assessment of causality  
• The Investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE to assess if they are ADEs/ /device deficiency.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying dis ease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study intervention administration will be 
considered and investigated.  
• For each ADE /device deficiency, the Investigator must  document in the medical  notes that 
he/she has reviewed the ADE/ device deficiency and has provided an assessment of causality.  
•  
 
Follow -up of ADE /device deficiency  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_368819]/or causality of the ADE/ device deficiency as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consul tation with other health care professionals.  
• New or updated information will be recorded in the originally completed CRF.  
• The Investigator will submit any updated ADE data to UCB  within 24 hours of receipt of the 
information.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 71 of 78 10.8 Appendix 8: Rapid alert proc edures  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 72 of 78 10.9 Appendix 9: Country -specific requirements  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 73 of 78 10.10  Appendix 10: Abbreviations and trademarks  
Ab antibody  
ADAb  anti-drug antibody  
ADE  adverse device effect  
AE adverse event  
AI auto-injector  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANOVA  analysis of variance  
AST  aspartate aminotransferase  
AUC  area under the plasma concentration -time curve from time zero to 
infinity  
AUC (0-t)  area under the plasma concentration -time curve from time zero to the 
last quanti fiable concentration  
%AUC ex percentage of the AUC extrapolated from C last 
axSpA  axial spondyloarthritis  
BE bioequivalence  
BMI  body mass index  
BP blood pressure  
CI confidence interval  
CL/F  apparent total body clearance  
Clast last observed quantifiable plasma drug concentration  
Cmax  maximum observed plasma drug concentration  
COVID -[ADDRESS_1136908]  
LDH  lactate dehydrogenase  
mAb  monoclonal antibody  
MedDRA® Medical Dictionary for Regulatory Activities  
PFS prefilled syringe  
PK pharmacokinetics  
PKS Pharmacokinetic Set  
PsA psoriatic arthritis  
PSO psoriasis  
QTcF  QT interval corrected using Fridericia’s formula  
RT-PCR  reverse transcriptase polymerase chain reaction  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SARS -CoV -2 severe acute respi[INVESTIGATOR_6507] 2  
SAS® Statistical Analysis System  
sc subcutaneous  
SD standard deviation  
SFU Safety Follow -Up 
SOP standard operating procedure  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136909]  upper limit of normal  
Vz/F  apparent volume of distribution  
WOCBP  women of childbearing potential  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 76 of 78 10.11  Appendix 11: Sample size estimation parameters  
Study  Formulation  Parameter  CV%  GeoMean 
ratio  Comments  
UP0033  
n=63 
per arm  SS 1mL  AUC  31.1 97.8 vs TN 1mL, CV% is from individual 
comparisons data  
Cmax 28 96.5 vs TN 1mL, CV% is from individual 
comparisons data  
AI 1mL  AUC  29.9 102 vs TN 1mL, CV% is from individual 
comparisons data  
Cmax 22.9 98.25  vs TN 1mL, CV% is from individual 
comparisons data  
TN 1mL  AUC  32.1   
Cmax 30.5   
UP0068  
n=~18 
per arm  SS 2mL  AUC  32.8 103.4  vs SS 2x1mL, F inal Report, CV% is 
from i ndividual comparison  
Cmax 25.4 104.0  vs SS 2x1mL, Final Report, CV% is 
from i ndividual comparison  
AI 2mL  AUC  28.6 115.0  vs AI 2x1mL, Final Report, CV% is 
from i ndividual comparison  
Cmax 24.7 114.3  vs AI 2x1mL, Final Report, CV% is 
from i ndividual comparison  
AI=auto -injector; AUC=area under the plasma concentration -time curve from time zero to infinity; 
Cmax=maximum observed plasma drug concentration; CV=coefficient of variation; Geomean=geometric mean; 
SS=safety syringe; TN=True North  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   21 Mar 2022  
Clinical Study Protocol Amendment 1  Bimekizumab  UP0119  
   
Confidential  Page 77 of 78 10.12  Appendix 12: Protocol amendment history  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.  
11 REFERENCES  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
EMEA/H/SA/3306/1/FU/1/2017/III Sep 2017.  
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
ISO [ZIP_CODE]:2020 Clinical Investigations of medical devices for human  subjects – Good Clinical 
Practice.  
Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on 
medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation 
(EC) No 1223/2009 and repealing Council  Directives 90/385/EEC and 93/42/EEC.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_1136910] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
Approval Signatures
Name: [CONTACT_25764]0119-protocol-amend-1
Version: 2 . 0
Document Number: CLIN-000185658
Title: UP0119 Protocol
Approved Date: [ADDRESS_1136911]: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 23-Mar-2022 15:28:16 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Medical
Date of Signature: 24-Mar-2022 07:24:15 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Management Approval
Date of Signature: 24-Mar-2022 08:53:17 GMT[PHONE_006]
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.